Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:44:18 ON 28 SEP 2006

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 12:44:27 ON 28 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Sep 2006  VOL 145 ISS 14
FILE LAST UPDATED: 27 Sep 2006  (20060927/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 20040146955/pn
L1            1 US 20040146955/PN
                (US2004146955/PN)

=> sel rn
E1 THROUGH E108 ASSIGNED

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.49       2.70

FILE 'REGISTRY' ENTERED AT 12:44:43 ON 28 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 SEP 2006  HIGHEST RN 909000-49-3
DICTIONARY FILE UPDATES:  27 SEP 2006  HIGHEST RN 909000-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
```

conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s e1-e108
             1 138-39-6/BI
               (138-39-6/RN)
             1 3523-95-3/BI
               (3523-95-3/RN)
             1 35303-76-5/BI
               (35303-76-5/RN)
             1 63-74-1/BI
               (63-74-1/RN)
             1 120-97-8/BI
               (120-97-8/RN)
             1 120279-96-1/BI
               (120279-96-1/RN)
             1 121-30-2/BI
               (121-30-2/RN)
             1 138-41-0/BI
               (138-41-0/RN)
             1 138890-62-7/BI
               (138890-62-7/RN)
             1 14949-00-9/BI
               (14949-00-9/RN)
             1 165668-41-7/BI
               (165668-41-7/RN)
             1 2153-13-1/BI
               (2153-13-1/RN)
             1 215998-40-6/BI
               (215998-40-6/RN)
             1 215998-42-8/BI
               (215998-42-8/RN)
             1 215998-44-0/BI
               (215998-44-0/RN)
             1 215998-46-2/BI
               (215998-46-2/RN)
             1 215998-48-4/BI
               (215998-48-4/RN)
             1 215998-50-8/BI
               (215998-50-8/RN)
             1 215998-52-0/BI
               (215998-52-0/RN)
             1 215998-54-2/BI
               (215998-54-2/RN)
             1 215998-56-4/BI
               (215998-56-4/RN)
             1 215998-58-6/BI
               (215998-58-6/RN)
             1 215998-60-0/BI
               (215998-60-0/RN)
             1 215998-62-2/BI
               (215998-62-2/RN)
             1 215998-64-4/BI
               (215998-64-4/RN)
             1 215998-66-6/BI
               (215998-66-6/RN)
```

1 215998-68-8/BI
(215998-68-8/RN)
1 215998-70-2/BI
(215998-70-2/RN)
1 215998-72-4/BI
(215998-72-4/RN)
1 215998-74-6/BI
(215998-74-6/RN)
1 215998-76-8/BI
(215998-76-8/RN)
1 215998-78-0/BI
(215998-78-0/RN)
1 215998-80-4/BI
(215998-80-4/RN)
1 215998-82-6/BI
(215998-82-6/RN)
1 215998-84-8/BI
(215998-84-8/RN)
1 215998-86-0/BI
(215998-86-0/RN)
1 215998-88-2/BI
(215998-88-2/RN)
1 215998-90-6/BI
(215998-90-6/RN)
1 215998-92-8/BI
(215998-92-8/RN)
1 215998-94-0/BI
(215998-94-0/RN)
1 215998-96-2/BI
(215998-96-2/RN)
1 215998-98-4/BI
(215998-98-4/RN)
1 215999-00-1/BI
(215999-00-1/RN)
1 215999-02-3/BI
(215999-02-3/RN)
1 215999-04-5/BI
(215999-04-5/RN)
1 215999-06-7/BI
(215999-06-7/RN)
1 215999-08-9/BI
(215999-08-9/RN)
1 215999-10-3/BI
(215999-10-3/RN)
1 215999-12-5/BI
(215999-12-5/RN)
1 215999-14-7/BI
(215999-14-7/RN)
1 215999-16-9/BI
(215999-16-9/RN)
1 215999-18-1/BI
(215999-18-1/RN)
1 216885-10-8/BI
(216885-10-8/RN)
1 2368-84-5/BI
(2368-84-5/RN)
1 244122-00-7/BI
(244122-00-7/RN)
1 259131-75-4/BI
(259131-75-4/RN)
1 29927-14-8/BI
(29927-14-8/RN)

1 3306-62-5/BI
(3306-62-5/RN)
1 345970-47-0/BI
(345970-47-0/RN)
1 345970-48-1/BI
(345970-48-1/RN)
1 35203-91-9/BI
(35203-91-9/RN)
1 4392-54-5/BI
(4392-54-5/RN)
1 452-35-7/BI
(452-35-7/RN)
1 53297-68-0/BI
(53297-68-0/RN)
1 53297-69-1/BI
(53297-69-1/RN)
1 547-52-4/BI
(547-52-4/RN)
1 554-57-4/BI
(554-57-4/RN)
1 59-66-5/BI
(59-66-5/RN)
1 60154-06-5/BI
(60154-06-5/RN)
1 606-25-7/BI
(606-25-7/RN)
1 654-62-6/BI
(654-62-6/RN)
1 67472-44-0/BI
(67472-44-0/RN)
1 688805-64-3/BI
(688805-64-3/RN)
1 688805-66-5/BI
(688805-66-5/RN)
1 688805-68-7/BI
(688805-68-7/RN)
1 688805-70-1/BI
(688805-70-1/RN)
1 688805-72-3/BI
(688805-72-3/RN)
1 688805-74-5/BI
(688805-74-5/RN)
1 688805-76-7/BI
(688805-76-7/RN)
1 688805-78-9/BI
(688805-78-9/RN)
1 688805-80-3/BI
(688805-80-3/RN)
1 688805-82-5/BI
(688805-82-5/RN)
1 688805-84-7/BI
(688805-84-7/RN)
1 688805-86-9/BI
(688805-86-9/RN)
1 688805-87-0/BI
(688805-87-0/RN)
1 688805-89-2/BI
(688805-89-2/RN)
1 688805-91-6/BI
(688805-91-6/RN)
1 688805-93-8/BI
(688805-93-8/RN)

```
              1 688805-97-2/BI
                (688805-97-2/RN)
              1 688805-99-4/BI
                (688805-99-4/RN)
              1 688806-01-1/BI
                (688806-01-1/RN)
              1 700378-86-5/BI
                (700378-86-5/RN)
              1 78160-85-7/BI
                (78160-85-7/RN)
              1 78160-87-9/BI
                (78160-87-9/RN)
              1 79783-03-2/BI
                (79783-03-2/RN)
              1 829-71-0/BI
                (829-71-0/RN)
              1 83439-56-9/BI
                (83439-56-9/RN)
              1 86029-46-1/BI
                (86029-46-1/RN)
              1 878502-00-2/BI
                (878502-00-2/RN)
              1 878502-01-3/BI
                (878502-01-3/RN)
              1 878502-02-4/BI
                (878502-02-4/RN)
              1 878502-03-5/BI
                (878502-03-5/RN)
              1 878502-04-6/BI
                (878502-04-6/RN)
              1 878502-05-7/BI
                (878502-05-7/RN)
              1 878502-06-8/BI
                (878502-06-8/RN)
              1 88615-09-2/BI
                (88615-09-2/RN)
              1 9001-03-0/BI
                (9001-03-0/RN)
              1 98-18-0/BI
                (98-18-0/RN)
L2          108 (138-39-6/BI OR 3523-95-3/BI OR 35303-76-5/BI OR 63-74-1/BI OR
                120-97-8/BI OR 120279-96-1/BI OR 121-30-2/BI OR 138-41-0/BI OR
                138890-62-7/BI OR 14949-00-9/BI OR 165668-41-7/BI OR 2153-13-1/BI
                OR 215998-40-6/BI OR 215998-42-8/BI OR 215998-44-0/BI OR 215998-
                46-2/BI OR 215998-48-4/BI OR 215998-50-8/BI OR 215998-52-0/BI OR
                215998-54-2/BI OR 215998-56-4/BI OR 215998-58-6/BI OR 215998-60-0
                /BI OR 215998-62-2/BI OR 215998-64-4/BI OR 215998-66-6/BI OR
                215998-68-8/BI OR 215998-70-2/BI OR 215998-72-4/BI OR 215998-74-6
                /BI OR 215998-76-8/BI OR 215998-78-0/BI OR 215998-80-4/BI OR
                215998-82-6/BI OR 215998-84-8/BI OR 215998-86-0/BI OR 215998-88-2
                /BI OR 215998-90-6/BI OR 215998-92-8/BI OR 215998-94-0/BI OR
                215998-96-2/BI OR 215998-98-4/BI OR 215999-00-1/BI OR 215999-02-3
                /BI OR 215999-04-5/BI OR 215999-06-7/BI OR 215999-08-9/BI OR
                215999-10-3/BI OR 215999-12-5/BI OR 215999-14-7/BI OR 215999-16-9
                /BI OR 215999-18-1/BI OR 216885-10-8/BI OR 2368-84-5/BI OR 244122
                -00-7/BI OR 259131-75-4/BI OR 2992

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.44       3.14
```

FILE 'CAPLUS' ENTERED AT 12:44:58 ON 28 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 27 Sep 2006 (20060927/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l2
L3       22388 L2

=> s l2/thu
         22388 L2
        816051 THU/RL
L4        1169 L2/THU
                (L2 (L) THU/RL)

=> s cancer? or tumor? or neoplas?
        307106 CANCER?
        442741 TUMOR?
        464671 NEOPLAS?
L5      733490 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 (l) l5
L6          67 L4 (L) L5

=> s l6 not py>2002
       4389687 PY>2002
L7          18 L6 NOT PY>2002

=> d ibib 1-18

L7   ANSWER 1 OF 18  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2003:153905  CAPLUS
DOCUMENT NUMBER:         138:265037
TITLE:                   Indisulam Eisai
AUTHOR(S):               Supuran, Claudiu T.
CORPORATE SOURCE:        Universita degli Studi di Firenze, Dipartimento di
                         Chimica, Sesto Fiorentino, I-50019, Italy
SOURCE:                  IDrugs (2002), 5(11), 1075-1079
                         CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER:               PharmaPress Ltd.
DOCUMENT TYPE:           Journal; General Review
LANGUAGE:                English
REFERENCE COUNT:         33    THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L7 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:875612 CAPLUS
DOCUMENT NUMBER: 138:395176
TITLE: E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer
AUTHOR(S): van Kesteren, Charlotte; Beijnen, Jos H.; Schellens, Jan H. M.
CORPORATE SOURCE: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, 1066 EC, Neth.
SOURCE: Anti-Cancer Drugs (2002), 13(10), 989-997
CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:804494 CAPLUS
DOCUMENT NUMBER: 138:362245
TITLE: An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients
AUTHOR(S): van den Bongard, H. J. G. Desiree; Pluim, Dick; Rosing, Hilde; Nan-Offeringa, Lianda; Schot, Margaret; Ravic, Miroslav; Schellens, Jan H. M.; Beijnen, Jos H.
CORPORATE SOURCE: Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, 1066 EC, Neth.
SOURCE: Anti-Cancer Drugs (2002), 13(8), 807-814
CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:708041 CAPLUS
DOCUMENT NUMBER: 137:241842
TITLE: Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer
AUTHOR(S): Raymond, E.; ten Bokkel Huinink, W. W.; Taieb, J.; Beijnen, J. H.; Faivre, S.; Wanders, J.; Ravic, M.; Fumoleau, P.; Armand, J. P.; Schellens, J. H. M.
CORPORATE SOURCE: European Organization for the Research and Treatment of Cancer Early Clinical Study Group, Institut Gustave-Roussy, Villejuif, 94805, Fr.
SOURCE: Journal of Clinical Oncology (2002), 20(16), 3508-3521
CODEN: JCONDN; ISSN: 0732-183X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:603243 CAPLUS
DOCUMENT NUMBER: 138:163096

TITLE: Acetazolamide suppresses tumor metastasis and related protein expression in mice bearing Lewis lung carcinoma
AUTHOR(S): Xiang, Yang; Ma, Bing; Li, Tao; Yu, He-Ming; Li, Xue-Jun
CORPORATE SOURCE: Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100083, Peop. Rep. China
SOURCE: Acta Pharmacologica Sinica (2002), 23(8), 745-751
CODEN: APSCG5; ISSN: 1671-4083
PUBLISHER: Science Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:346758 CAPLUS
DOCUMENT NUMBER: 138:61168
TITLE: Transnasal chemotherapy of the brain tumor utilizing the direct transport pathway between the nose and the cerebrospinal fluid
AUTHOR(S): Sakane, T.; Yamashita, S.; Yata, N.; Sezaki, H.; Tokunaga, Y.; Shibata, S.
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Setsunan University, Osaka, 573-0101, Japan
SOURCE: Proceedings - 28th International Symposium on Controlled Release of Bioactive Materials and 4th Consumer & Diversified Products Conference, San Diego, CA, United States, June 23-27, 2001 (2001), Volume 1, 225-226. Controlled Release Society: Minneapolis, Minn.
CODEN: 69CNY8
DOCUMENT TYPE: Conference
LANGUAGE: English
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:724918 CAPLUS
DOCUMENT NUMBER: 136:395443
TITLE: Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells
AUTHOR(S): Fukuoka, Kazuya; Usuda, Jitsuo; Iwamoto, Yasuo; Fukumoto, Hisao; Nakamura, Takashi; Yoneda, Takahiro; Narita, Nobuhiro; Saijo, Nagahiro; Nishio, Kazuto
CORPORATE SOURCE: Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
SOURCE: Investigational New Drugs (2001), 19(3), 219-227
CODEN: INNDDK; ISSN: 0167-6997
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:455364 CAPLUS
DOCUMENT NUMBER: 133:38216
TITLE: Preparation of sulfanilamide derivative for diagnosis and treatment of tumor

INVENTOR(S): Tan, Lisong; Li, Libin; Su, Bo
PATENT ASSIGNEE(S): Shanghai No.1 Pulmonary Department Hospital, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 24 pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1214264	A	19990421	CN 1997-106657	19971015
PRIORITY APPLN. INFO.:			CN 1997-106657	19971015

L7 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:176258 CAPLUS
DOCUMENT NUMBER: 132:303120
TITLE: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro
AUTHOR(S): Parkkila, Seppo; Rajaniemi, Hannu; Parkkila, Anna-Kaisa; Kivela, Jyrki; Waheed, Abdul; Pastorekova, Silvia; Pastorek, Jaromir; Sly, William S.
CORPORATE SOURCE: Departments of Anatomy and Cell Biology, Clinical Chemistry, 90014 University of Oulu, Finland
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2000), 97(5), 2220-2224 CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:712802 CAPLUS
DOCUMENT NUMBER: 132:227295
TITLE: Transnasal delivery of anticancer drugs to the brain tumor: a new strategy for brain tumor chemotherapy
AUTHOR(S): Shingaki, Tomotaka; Sakane, Toshiyasu; Yamashita, Shinji; Sezaki, Hitoshi; Tokunaga, Yoshiharu; Shibata, Shobu
CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Setsunan University, Setsunan, Japan
SOURCE: Drug Delivery System (1999), 14(5), 365-371 CODEN: DDSYEI; ISSN: 0913-5006
PUBLISHER: Nippon DDS Gakkai Jimukyoku
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

L7 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:773985 CAPLUS
DOCUMENT NUMBER: 130:248135
TITLE: Chinese herbs nephropathy-associated slimming regimen induces tumors in the forestomach but no interstitial nephropathy in rats
AUTHOR(S): Cosyns, Jean-Pierre; Goebbels, Rose-Marie; Liberton, Vinciane; Schmeiser, Heinz H.; Bieler, Christian A.; Bernard, Alfred M.
CORPORATE SOURCE: Cliniques Universitaires St. Luc, Department of Pathology, ANPS 1712 Catholic University of Louvain Medical School, Brussels, B-1200, Belg.

SOURCE: Archives of Toxicology (1998), 72(11), 738-743
CODEN: ARTODN; ISSN: 0340-5761
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:750281 CAPLUS
DOCUMENT NUMBER: 130:208022
TITLE: Carbonic anhydrase II as a marker of malignant features for colorectal cancer
AUTHOR(S): Bekku, Shinya; Yamamoto, Tetsuhisa; Mochizuki, Hidetaka
CORPORATE SOURCE: Department of First Surgery, National Defence Medical College, Japan
SOURCE: Igaku no Ayumi (1998), 186(12), 891-892
CODEN: IGAYAY; ISSN: 0039-2359
PUBLISHER: Ishiyaku Shuppan
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

L7 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:640364 CAPLUS
DOCUMENT NUMBER: 129:242205
TITLE: Rapid method of cancer diagnosis by measuring activation of carbonic anhydrase II by blood serum tumor markers
INVENTOR(S): Puscas, Ioan; Puscas, Iuliana Carmen; Coltau, Marcela; Domuta, Gabriela; Baican, Michael
PATENT ASSIGNEE(S): Rom.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841649	A2	19980924	WO 1998-EP1465	19980313
WO 9841649	A3	19981223		
W: AL, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RO 114835	B3	19990730	RO 1997-502	19970317
CA 2284632	AA	19980924	CA 1998-2284632	19980313
AU 9867298	A1	19981012	AU 1998-67298	19980313
AU 738843	B2	20010927		
EP 972072	A2	20000119	EP 1998-912475	19980313
EP 972072	B1	20011121		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, SI, LT, FI, RO				
BR 9808373	A	20000523	BR 1998-8373	19980313
NZ 337850	A	20010727	NZ 1998-337850	19980313
JP 2001524815	T2	20011204	JP 1998-540117	19980313
AT 209256	E	20011215	AT 1998-912475	19980313

MX 9908488	A	20000531	MX 1999-8488		19990915
PRIORITY APPLN. INFO.:			RO 1997-502	A	19970317
			WO 1998-EP1465	W	19980313

L7 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:465838 CAPLUS
DOCUMENT NUMBER: 129:228986
TITLE: Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation
AUTHOR(S): Saarnio, Juha; Parkkila, Seppo; Parkkila, Anna-Kaisa; Haukipuro, Kari; Pastorekova, Silvia; Pastorek, Jaromir; Kairaluoma, Matti I.; Karttunen, Tuomo J.
CORPORATE SOURCE: Department of Surgery, University of Oulu, Oulu, SF-90220, Finland
SOURCE: American Journal of Pathology (1998), 153(1), 279-285
CODEN: AJPAA4; ISSN: 0002-9440
PUBLISHER: American Society for Investigative Pathology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:334002 CAPLUS
DOCUMENT NUMBER: 129:51697
TITLE: The immunoassay of carbonic anhydrase for screening colon cancer
INVENTOR(S): Yokoyama, Yukio
PATENT ASSIGNEE(S): Yokoyama, Yukio, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 2 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10132822	A2	19980522	JP 1996-327494	19961101
PRIORITY APPLN. INFO.:			JP 1996-327494	19961101

L7 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:537618 CAPLUS
DOCUMENT NUMBER: 127:130994
TITLE: Use of carbonic anhydrase inhibitors to prepare a drug for cancer therapy
INVENTOR(S): Lang, Hans Jochen; Gericke, Dietmar
PATENT ASSIGNEE(S): Hoechst A.-G., Germany; Lang, Hans Jochen; Gericke, Dietmar
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725039	A1	19970717	WO 1996-EP5793	19961220
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU,				

IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN,
MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
MR, NE, SN, TD, TG

DE 19600721	A1	19970717	DE 1996-19600721		19960112
AU 9713046	A1	19970801	AU 1997-13046		19961220
PRIORITY APPLN. INFO.:			DE 1996-19600721	A	19960112
			WO 1996-EP5793	W	19961220

L7 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:262841 CAPLUS
DOCUMENT NUMBER: 124:314359
TITLE: A marker antigen for non-small cell lung cancer and a cDNA encoding it and their uses
INVENTOR(S): Torczynski, Richard M.; Bollon, Arthur P.
PATENT ASSIGNEE(S): Cytoclonal Pharmaceutics, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9602552	A1	19960201	WO 1995-US9145		19950719
W: AU, BR, CA, CN, FI, JP, KE, KR, LK, MN, MX, NO, NZ, PL, RU, UA, US					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
US 5589579	A	19961231	US 1994-276919		19940719
CA 2195403	AA	19960201	CA 1995-2195403		19950719
AU 9533592	A1	19960216	AU 1995-33592		19950719
AU 700915	B2	19990114			
EP 804451	A1	19971105	EP 1995-930093		19950719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
BR 9508417	A	19971118	BR 1995-8417		19950719
JP 10503087	T2	19980324	JP 1995-505257		19950719
US 5773579	A	19980630	US 1997-776088		19970121
PRIORITY APPLN. INFO.:			US 1994-276919	A	19940719
			WO 1995-US9145	W	19950719

L7 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:475517 CAPLUS
DOCUMENT NUMBER: 73:75517
TITLE: Oncostatic activities of some fluoro compounds against Ehrlich carcinoma in mice
AUTHOR(S): Nakahara, Toru; Miyamoto, Fumiko; Kayama, Tokihiko
CORPORATE SOURCE: Wakayama Univ., Wakayama, Japan
SOURCE: Wakayama Daigaku Gakugeigakubu Kiyo, Shizenkagaku (1968), No. 18, 15-17
CODEN: WDGKAJ; ISSN: 0507-8318
DOCUMENT TYPE: Journal
LANGUAGE: Japanese

=> d his

(FILE 'HOME' ENTERED AT 12:44:18 ON 28 SEP 2006)

FILE 'CAPLUS' ENTERED AT 12:44:27 ON 28 SEP 2006
L1 1 S US 20040146955/PN
SEL RN

```
     FILE 'REGISTRY' ENTERED AT 12:44:43 ON 28 SEP 2006
L2          108 S E1-E108

     FILE 'CAPLUS' ENTERED AT 12:44:58 ON 28 SEP 2006
L3        22388 S L2
L4         1169 S L2/THU
L5       733490 S CANCER? OR TUMOR? OR NEOPLAS?
L6           67 S L4 (L) L5
L7           18 S L6 NOT PY>2002

=> s l7 and sulfonam?
         33901 SULFONAM?
L8           5 L7 AND SULFONAM?

=> d ibib 1-5

L8   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:153905  CAPLUS
DOCUMENT NUMBER:          138:265037
TITLE:                    Indisulam Eisai
AUTHOR(S):                Supuran, Claudiu T.
CORPORATE SOURCE:         Universita degli Studi di Firenze, Dipartimento di
                          Chimica, Sesto Fiorentino, I-50019, Italy
SOURCE:                   IDrugs (2002), 5(11), 1075-1079
                          CODEN: IDRUFN; ISSN: 1369-7056
PUBLISHER:                PharmaPress Ltd.
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
REFERENCE COUNT:          33    THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:875612  CAPLUS
DOCUMENT NUMBER:          138:395176
TITLE:                    E7070: a novel synthetic sulfonamide
                          targeting the cell cycle progression for the treatment
                          of cancer
AUTHOR(S):                van Kesteren, Charlotte; Beijnen, Jos H.; Schellens,
                          Jan H. M.
CORPORATE SOURCE:         Department of Pharmacy and Pharmacology, The
                          Netherlands Cancer Institute/Slotervaart Hospital,
                          Amsterdam, 1066 EC, Neth.
SOURCE:                   Anti-Cancer Drugs (2002), 13(10), 989-997
                          CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER:                Lippincott Williams & Wilkins
DOCUMENT TYPE:            Journal; General Review
LANGUAGE:                 English
REFERENCE COUNT:          33    THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 3 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2002:804494  CAPLUS
DOCUMENT NUMBER:          138:362245
TITLE:                    An excretion balance and pharmacokinetic study of the
                          novel anticancer agent E7070 in cancer patients
AUTHOR(S):                van den Bongard, H. J. G. Desiree; Pluim, Dick;
                          Rosing, Hilde; Nan-Offeringa, Lianda; Schot, Margaret;
                          Ravic, Miroslav; Schellens, Jan H. M.; Beijnen, Jos H.
CORPORATE SOURCE:         Department of Pharmacy and Pharmacology, Slotervaart
                          Hospital/The Netherlands Cancer Institute, Amsterdam,
                          1066 EC, Neth.
```

SOURCE: Anti-Cancer Drugs (2002), 13(8), 807-814
CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:708041 CAPLUS
DOCUMENT NUMBER: 137:241842
TITLE: Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer
AUTHOR(S): Raymond, E.; ten Bokkel Huinink, W. W.; Taieb, J.; Beijnen, J. H.; Faivre, S.; Wanders, J.; Ravic, M.; Fumoleau, P.; Armand, J. P.; Schellens, J. H. M.
CORPORATE SOURCE: European Organization for the Research and Treatment of Cancer Early Clinical Study Group, Institut Gustave-Roussy, Villejuif, 94805, Fr.
SOURCE: Journal of Clinical Oncology (2002), 20(16), 3508-3521
CODEN: JCONDN; ISSN: 0732-183X
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:724918 CAPLUS
DOCUMENT NUMBER: 136:395443
TITLE: Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells
AUTHOR(S): Fukuoka, Kazuya; Usuda, Jitsuo; Iwamoto, Yasuo; Fukumoto, Hisao; Nakamura, Takashi; Yoneda, Takahiro; Narita, Nobuhiro; Saijo, Nagahiro; Nishio, Kazuto
CORPORATE SOURCE: Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan
SOURCE: Investigational New Drugs (2001), 19(3), 219-227
CODEN: INNDDK; ISSN: 0167-6997
PUBLISHER: Kluwer Academic Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:44:18 ON 28 SEP 2006)

FILE 'CAPLUS' ENTERED AT 12:44:27 ON 28 SEP 2006
L1 1 S US 20040146955/PN
SEL RN

FILE 'REGISTRY' ENTERED AT 12:44:43 ON 28 SEP 2006
L2 108 S E1-E108

FILE 'CAPLUS' ENTERED AT 12:44:58 ON 28 SEP 2006
L3 22388 S L2

```
L4         1169 S L2/THU
L5       733490 S CANCER? OR TUMOR? OR NEOPLAS?
L6           67 S L4 (L) L5
L7           18 S L6 NOT PY>2002
L8            5 S L7 AND SULFONAM?

=> d l7 ibib abs kwic 8, 9, 16

L7   ANSWER 8 OF 18  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2000:455364  CAPLUS
DOCUMENT NUMBER:          133:38216
TITLE:                    Preparation of sulfanilamide derivative for diagnosis
                          and treatment of tumor
INVENTOR(S):              Tan, Lisong; Li, Libin; Su, Bo
PATENT ASSIGNEE(S):       Shanghai No.1 Pulmonary Department Hospital, Peop.
                          Rep. China
SOURCE:                   Faming Zhuanli Shenqing Gongkai Shuomingshu, 24 pp.
                          CODEN: CNXXEV
DOCUMENT TYPE:            Patent
LANGUAGE:                 Chinese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     CN 1214264            A     19990421    CN 1997-106657         19971015
PRIORITY APPLN. INFO.:                       CN 1997-106657         19971015
AB   The sulfanilamide derivative R1-1,4-phenylene-SO2-N(R2)-L-R3 (R1 = NH2, CH3,
     or CH3CONH, etc.; R2 = pyrimidinyl, pyrazinyl, or other heterocycle; L =
     polyglycol, metyleneformylhexanediamine, or methylenecarbonylaminohexanoic
     acid, etc.; and R3 = anti-tumor drug, or complexant for 111In, 99mTc,
     188Re, 186Re, 90Y, or 67Cu, etc.) is used for diagnosis and treatment of
     tumor.  The sulfanilamide intermediate (I) (N-acetylsulfadiazine-PEG-
     isopropanol-butanediamine) is prepared by dissolving sulfadiazine in NaOH
     solution, regulating pH to 10-11, precipitating with ethanol, polymerizing with
     epoxyethane at 85° for 3-5 d, terminating with methanol to obtain
     N-acetylsulfadiazine-PEG, acetylating with acetic anhydride in NaHCO3
     buffer solution (pH 9.0-10.0), allowing to react with chloromethyloxirane at
     50° for 3 h, and substituting with butanediamine in the presence of
     DCCI.  The sulfanilamide intermediate (II) (N-acetylsulfadiazine-
     methylenecarboxylhexanediamine) is prepared by acetylating sulfadiazine with
     acetic anhydride for 30 min, dissolving in NaOH solution, condensation with
     iodoacetic acid at 55° and pH 10-11 for 5 h, substituting with
     hexanediamine in the presence of DCCI and in THF at 4° for 2, and
     extracting with butanol.  The sulfanilamide derivative is prepared by
dissolving (I)
     in chloroform, condensation with cyclic DTPA for 24 h, precipitating with
EtOAc,
     and recrystg. with chloroform or EtOAc.  The sulfanilamide derivative-drug
     composite is prepared by condensation of the sulfanilamide derivative with
     activated drug in NaHCO3 buffer solution (pH 9.0) for 30 min, and separating
with
     Sephadex G10 or LH20 column chromatog.  Sulfadiazine may be replaced by
     sulfapyrazine.  The activated drug is selected from carboxy-activated
     methotrexate, pentanedioic acid-activated mitomycin C, and pentanedioic
     acid-activated adriamycin.
IT   63-74-1D, Sulfanilamide, antitumor derivs.   10098-91-6D, 90Y,
     sulfanilamide complex, biological studies   14133-76-7D, Technetium,
     isotope of mass 99, sulfanilamide complex, biological studies
     14378-26-8D, 188Re, sulfanilamide complex, biological studies
     14998-63-1D, 186Re, sulfanilamide complex, biological studies
     15750-15-9D, 111In, sulfanilamide complex, biological studies
```

15757-86-5D, 67Cu, sulfanilamide complex, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of sulfanilamide derivative for diagnosis and treatment of tumor)

L7 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:176258 CAPLUS
DOCUMENT NUMBER: 132:303120
TITLE: Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro
AUTHOR(S): Parkkila, Seppo; Rajaniemi, Hannu; Parkkila, Anna-Kaisa; Kivela, Jyrki; Waheed, Abdul; Pastorekova, Silvia; Pastorek, Jaromir; Sly, William S.
CORPORATE SOURCE: Departments of Anatomy and Cell Biology, Clinical Chemistry, 90014 University of Oulu, Finland
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2000), 97(5), 2220-2224
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Acidification of the extracellular milieu of malignant tumors is reported to increase the invasive behavior of cancer cells. In normal tissues, production of acid is catalyzed by carbonic anhydrases (CAs), some of which are known to be overexpressed in certain cancers. To investigate the functional role of CA activity in such cancer cells, the authors analyzed the effect of acetazolamide, a potent CA inhibitor, on the invasive capacity of four renal carcinoma cell lines (Caki-1, Caki-2, ACHN, and A-498). The authors found that 10 μM acetazolamide inhibited the relative invasion rate of these cell lines between 18-74%. The Caki-2 and ACHN cell lines displayed the highest responsiveness, and their responses clearly depended on the acetazolamide concentration in the culture medium. Immunocytochem. and Western blotting results identified the presence of CA isoenzyme II in the cytoplasm of all four cell lines and CA XII on the plasma membrane in three of four cell lines. Because acetazolamide alone reduced invasiveness of these cancer cells in vitro, the authors conclude that the CAs overexpressed in these renal cancer cells contribute to invasiveness, at least in vitro, and suggest that CA inhibitors may also reduce invasiveness in other tumors that overexpress one or more CAs.
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 59-66-5, Acetazolamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of carbonic anhydrase in invasion of renal cancer cells in vitro and possible therapeutic role of carbonic anhydrase inhibitor acetazolamide)

L7 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:537618 CAPLUS
DOCUMENT NUMBER: 127:130994
TITLE: Use of carbonic anhydrase inhibitors to prepare a drug for cancer therapy
INVENTOR(S): Lang, Hans Jochen; Gericke, Dietmar
PATENT ASSIGNEE(S): Hoechst A.-G., Germany; Lang, Hans Jochen; Gericke, Dietmar
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725039	A1	19970717	WO 1996-EP5793	19961220
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19600721	A1	19970717	DE 1996-19600721	19960112
AU 9713046	A1	19970801	AU 1997-13046	19961220
PRIORITY APPLN. INFO.:			DE 1996-19600721 A	19960112
			WO 1996-EP5793 W	19961220

AB Carbonic anhydrase inhibitors such as acetazolamide are useful, alone or in association with chemotherapeutic agents, phys. treatments such as radiation therapy, or immunomodulators, for treatment of cancer (no data).

IT 59-66-5, Acetazolamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of carbonic anhydrase inhibitors for cancer therapy)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	51.27	54.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

FILE 'REGISTRY' ENTERED AT 12:50:27 ON 28 SEP 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2006 HIGHEST RN 909000-49-3
DICTIONARY FILE UPDATES: 27 SEP 2006 HIGHEST RN 909000-49-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s 59-66-5

```
L9           1 59-66-5
                 (59-66-5/RN)

=> s l9 and l2
L10          1 L9 AND L2

=> d hitstr
'HITSTR' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual
fields or predefined formats.  The predefined substance formats
are:  (RN = CAS Registry Number)

REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid codes are used
SQN    - Protein sequence name information, includes RN

CALC   - Table of calculated properties
EPROP  - Table of experimental properties
PROP   - EPROP and CALC

Any CA File format may be combined with any substance format to
obtain CA references citing the substance.  The substance formats
must be cited first.  The CA File predefined formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented,
with text labels.

For additional information, please consult the following help
messages:
```

```
HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):end

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.44      54.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -2.25

FILE 'CAPLUS' ENTERED AT 12:51:02 ON 28 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Sep 2006  VOL 145 ISS 14
FILE LAST UPDATED: 27 Sep 2006  (20060927/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 12:44:18 ON 28 SEP 2006)

     FILE 'CAPLUS' ENTERED AT 12:44:27 ON 28 SEP 2006
L1            1 S US 20040146955/PN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 12:44:43 ON 28 SEP 2006
L2          108 S E1-E108

     FILE 'CAPLUS' ENTERED AT 12:44:58 ON 28 SEP 2006
L3        22388 S L2
L4         1169 S L2/THU
L5       733490 S CANCER? OR TUMOR? OR NEOPLAS?
L6           67 S L4 (L) L5
L7           18 S L6 NOT PY>2002
L8            5 S L7 AND SULFONAM?

     FILE 'REGISTRY' ENTERED AT 12:50:27 ON 28 SEP 2006
L9            1 S 59-66-5
L10           1 S L9 AND L2

     FILE 'CAPLUS' ENTERED AT 12:51:02 ON 28 SEP 2006
```

=> d l7 hitstr 1-18

L7 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 165668-41-7, Indisulam
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indisulam for potential treatment of cancer)
RN 165668-41-7 CAPLUS
CN 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 165668-41-7, E7070
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E7070, a novel synthetic sulfonamide targeting the cell cycle progression for treatment of cancer)
RN 165668-41-7 CAPLUS
CN 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

/ Structure 2 in file .gra /

L7 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 165668-41-7, E7070
RL: ADV (Adverse effect, including toxicity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E7070 excretion and pharmacokinetics in cancer patients)
RN 165668-41-7 CAPLUS
CN 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

/ Structure 3 in file .gra /

L7 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 165668-41-7, E7070
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetic study of E7070 infusion, novel chloroindolyl sulfonamide cell-cycle inhibitor, in advanced cancer patients)

RN 165668-41-7 CAPLUS
CN 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

/ Structure 4 in file .gra /

L7 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 59-66-5, Acetazolamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(acetazolamide suppresses tumor metastasis and related protein expression in mice bearing Lewis lung carcinoma)
RN 59-66-5 CAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

/ Structure 5 in file .gra /

L7 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 59-66-5, Acetazolamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(brain tumor chemotherapy using nasal delivery of drug to cerebrospinal fluid: effect of excipients)
RN 59-66-5 CAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

/ Structure 6 in file .gra /

L7 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 165668-41-7, E7070
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mechanisms of action of novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells)
RN 165668-41-7 CAPLUS
CN 1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- (9CI) (CA INDEX NAME)

/ Structure 7 in file .gra /

L7 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 63-74-1D, Sulfanilamide, antitumor derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of sulfanilamide derivative for diagnosis and treatment of tumor)
RN 63-74-1 CAPLUS
CN Benzenesulfonamide, 4-amino- (9CI) (CA INDEX NAME)

/ Structure 8 in file .gra /

L7 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 59-66-5, Acetazolamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(role of carbonic anhydrase in invasion of renal cancer cells in vitro and possible therapeutic role of carbonic anhydrase inhibitor acetazolamide)
RN 59-66-5 CAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

/ Structure 9 in file .gra /

L7 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 59-66-5
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transnasal delivery of anticancer drugs to brain tumor)
RN 59-66-5 CAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

/ Structure 10 in file .gra /

L7 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 59-66-5, Acetazolamide
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Chinese herbs nephropathy-associated slimming regimen induces tumors in the forestomach but no interstitial nephropathy in rats)
RN 59-66-5 CAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

/ Structure 11 in file .gra /

L7 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 9001-03-0
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(II; carbonic anhydrase II as a marker of malignant features for colorectal cancer)
RN 9001-03-0 CAPLUS
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 9001-03-0, Carbonic anhydrase
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical

study); BIOL (Biological study); USES (Uses)
(II; rapid method of cancer diagnosis by measuring activation of carbonic anhydrase II by blood serum tumor markers)
RN 9001-03-0 CAPLUS
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 9001-03-0, Carbonic anhydrase
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(isoenzyme IX; colorectal tumors expression of transmembrane carbonic anhydrase, MN/CA IX, with potential value as marker of cell proliferation in human)
RN 9001-03-0 CAPLUS
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 9001-03-0, Carbonate anhydrase
RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(fecal; immunoassay of carbonic anhydrase for screening colon cancer)
RN 9001-03-0 CAPLUS
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 59-66-5, Acetazolamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of carbonic anhydrase inhibitors for cancer therapy)
RN 59-66-5 CAPLUS
CN Acetamide, N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]- (9CI) (CA INDEX NAME)

/ Structure 12 in file .gra /

L7 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 9001-03-0, Carbonic anhydrase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as marker for non-small cell lung cancer; marker antigen for non-small cell lung cancer and cDNA encoding it and their uses)
RN 9001-03-0 CAPLUS
CN Dehydratase, carbonate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
IT 654-62-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(neoplasm inhibition by)
RN 654-62-6 CAPLUS
CN 1,3-Benzenedisulfonamide, 4-amino-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)

/ Structure 13 in file .gra /

=> d l7 ibib abs hitstr 8

L7 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:455364 CAPLUS
DOCUMENT NUMBER: 133:38216
TITLE: Preparation of sulfanilamide derivative for diagnosis and treatment of tumor
INVENTOR(S): Tan, Lisong; Li, Libin; Su, Bo
PATENT ASSIGNEE(S): Shanghai No.1 Pulmonary Department Hospital, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 24 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1214264	A	19990421	CN 1997-106657	19971015
PRIORITY APPLN. INFO.:			CN 1997-106657	19971015

AB The sulfanilamide derivative R1-1,4-phenylene-SO2-N(R2)-L-R3 (R1 = NH2, CH3, or CH3CONH, etc.; R2 = pyrimidinyl, pyrazinyl, or other heterocycle; L = polyglycol, metyleneformylhexanediamine, or methylenecarbonylaminohexanoic acid, etc.; and R3 = anti-tumor drug, or complexant for 111In, 99mTc, 188Re, 186Re, 90Y, or 67Cu, etc.) is used for diagnosis and treatment of tumor. The sulfanilamide intermediate (I) (N-acetylsulfadiazine-PEG-isopropanol-butanediamine) is prepared by dissolving sulfadiazine in NaOH solution, regulating pH to 10-11, precipitating with ethanol, polymerizing with epoxyethane at 85° for 3-5 d, terminating with methanol to obtain N-acetylsulfadiazine-PEG, acetylating with acetic anhydride in NaHCO3 buffer solution (pH 9.0-10.0), allowing to react with chloromethyloxirane at 50° for 3 h, and substituting with butanediamine in the presence of DCCI. The sulfanilamide intermediate (II) (N-acetylsulfadiazine-methylenecarboxylhexanediamine) is prepared by acetylating sulfadiazine with acetic anhydride for 30 min, dissolving in NaOH solution, condensation with iodoacetic acid at 55° and pH 10-11 for 5 h, substituting with hexanediamine in the presence of DCCI and in THF at 4° for 2, and extracting with butanol. The sulfanilamide derivative is prepared by dissolving (I) in chloroform, condensation with cyclic DTPA for 24 h, precipitating with EtOAc, and recrystg. with chloroform or EtOAc. The sulfanilamide derivative-drug composite is prepared by condensation of the sulfanilamide derivative with activated drug in NaHCO3 buffer solution (pH 9.0) for 30 min, and separating with Sephadex G10 or LH20 column chromatog. Sulfadiazine may be replaced by sulfapyrazine. The activated drug is selected from carboxy-activated methotrexate, pentanedioic acid-activated mitomycin C, and pentanedioic acid-activated adriamycin.
IT 63-74-1D, Sulfanilamide, antitumor derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of sulfanilamide derivative for diagnosis and treatment of tumor)
RN 63-74-1 CAPLUS
CN Benzenesulfonamide, 4-amino- (9CI) (CA INDEX NAME)

/ Structure 14 in file .gra /

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	39.41	94.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.75	-3.00

STN INTERNATIONAL LOGOFF AT 12:53:26 ON 28 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000

```
 NEWS  9  DEC 01  CAS REGISTRY updated with new ambiguity codes
 NEWS 10  DEC 11  CAS REGISTRY chemical nomenclature enhanced
 NEWS 11  DEC 14  WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 12  DEC 14  GBFULL and FRFULL enhanced with IPC 8 features and
                  functionality
 NEWS 13  DEC 18  CA/CAplus pre-1967 chemical substance index entries enhanced
                  with preparation role
 NEWS 14  DEC 18  CA/CAplus patent kind codes updated
 NEWS 15  DEC 18  MARPAT to CA/CAplus accession number crossover limit increased
                  to 50,000
 NEWS 16  DEC 18  MEDLINE updated in preparation for 2007 reload
 NEWS 17  DEC 27  CA/CAplus enhanced with more pre-1907 records
 NEWS 18  JAN 08  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 19  JAN 16  CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 20  JAN 16  IPC version 2007.01 thesaurus available on STN
 NEWS 21  JAN 16  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 22  JAN 22  CA/CAplus updated with revised CAS roles
 NEWS 23  JAN 22  CA/CAplus enhanced with patent applications from India
 NEWS 24  JAN 29  PHAR reloaded with new search and display fields
 NEWS 25  JAN 29  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:01:43 ON 31 JAN 2007

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 17:01:52 ON 31 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 JAN 2007  HIGHEST RN 918865-48-2
DICTIONARY FILE UPDATES:  30 JAN 2007  HIGHEST RN 918865-48-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s acetazolamide/cn
L1   1 ACETAZOLAMIDE/CN

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   5.40   5.61

FILE 'CAPLUS' ENTERED AT 17:02:23 ON 31 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 31 Jan 2007 VOL 146 ISS 6
FILE LAST UPDATED: 30 Jan 2007 (20070130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1/dgn
          2763 L1
         73491 DGN/RL
L2   11 L1/DGN
                (L1 (L) DGN/RL)

=> s l1
L3   2763 L1

=> s tumor? or cancer? or neoplas?
        456608 TUMOR?
        319712 CANCER?
        479213 NEOPLAS?
L4   756547 TUMOR? OR CANCER? OR NEOPLAS?

=> s l3 (L) l4
L5   37 L3 (L) L4

```
=> s l5 and l2
L6            0 L5 AND L2

=> s sulfonamid?
L7        34242 SULFONAMID?

=> s l7 (L) l4
L8          672 L7 (L) L4

=> s diagnos?
L9       275619 DIAGNOS?

=> s l9 and l8
L10          22 L9 AND L8

=> s carbonic anhydrase
          44312 CARBONIC
              1 CARBONICS
          44313 CARBONIC
                    (CARBONIC OR CARBONICS)
          12249 ANHYDRASE
            713 ANHYDRASES
          12291 ANHYDRASE
                    (ANHYDRASE OR ANHYDRASES)
L11       12141 CARBONIC ANHYDRASE
                    (CARBONIC(W)ANHYDRASE)

=> s l11 and l2
L12           0 L11 AND L2

=> s l12 and l3
L13           0 L12 AND L3

=> s l11 and l3
L14        1069 L11 AND L3

=> s l14 and l4
L15          45 L14 AND L4

=> s l14 and l5
L16          13 L14 AND L5

=> s l16 not py>2002
        4850131 PY>2002
L17           4 L16 NOT PY>2002

=> d ibib 1-4

L17  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2000:176258  CAPLUS
DOCUMENT NUMBER:          132:303120
TITLE:                    Carbonic anhydrase inhibitor
                          suppresses invasion of renal cancer cells in vitro
AUTHOR(S):                Parkkila, Seppo; Rajaniemi, Hannu; Parkkila,
                          Anna-Kaisa; Kivela, Jyrki; Waheed, Abdul; Pastorekova,
                          Silvia; Pastorek, Jaromir; Sly, William S.
CORPORATE SOURCE:         Departments of Anatomy and Cell Biology, Clinical
                          Chemistry, 90014 University of Oulu, Finland
SOURCE:                   Proceedings of the National Academy of Sciences of the
                          United States of America (2000), 97(5), 2220-2224
                          CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER:                National Academy of Sciences
```

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:537618 CAPLUS
DOCUMENT NUMBER: 127:130994
TITLE: Use of carbonic anhydrase inhibitors to prepare a drug for cancer therapy
INVENTOR(S): Lang, Hans Jochen; Gericke, Dietmar
PATENT ASSIGNEE(S): Hoechst A.-G., Germany; Lang, Hans Jochen; Gericke, Dietmar
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725039	A1	19970717	WO 1996-EP5793	19961220
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
DE 19600721	A1	19970717	DE 1996-19600721	19960112
AU 9713046	A	19970801	AU 1997-13046	19961220
PRIORITY APPLN. INFO.:			DE 1996-19600721 A	19960112
			WO 1996-EP5793 W	19961220

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:178180 CAPLUS
DOCUMENT NUMBER: 114:178180
TITLE: Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase
AUTHOR(S): Brown, Gregory M.; Morris, Carol A.; Mitnick, Mary Ann; Insogna, Karl L.
CORPORATE SOURCE: Sch. Med., Yale Univ., New Haven, CT, 06510, USA
SOURCE: Journal of Bone and Mineral Research (1990), 5(10), 1037-41
CODEN: JBMREJ; ISSN: 0884-0431
DOCUMENT TYPE: Journal
LANGUAGE: English

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1986:10594 CAPLUS
DOCUMENT NUMBER: 104:10594
TITLE: Antitumor pharmaceuticals containing 1-phthalidyl-5-fluorouracil and sulfonamides
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60126219	A	19850705	JP 1983-233269	19831209
PRIORITY APPLN. INFO.:			JP 1983-233269	19831209

=> d kwic 2-4

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Use of carbonic anhydrase inhibitors to prepare a drug for cancer therapy
AB Carbonic anhydrase inhibitors such as acetazolamide are useful, alone or in association with chemotherapeutic agents, phys. treatments such as radiation therapy, or. . .
ST carbonic anhydrase inhibitor cancer therapy
IT Antitumor agents
(use of carbonic anhydrase inhibitors for cancer therapy)
IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; use of carbonic anhydrase inhibitors for cancer therapy)
IT 59-66-5, Acetazolamide
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of carbonic anhydrase inhibitors for cancer therapy)

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
TI Treatment of humoral hypercalcemia of malignancy in rats with inhibitors of carbonic anhydrase
AB The enzyme carbonic anhydrase has been suggested as a critical participant in osteoclast-mediated bone resorption. In humoral hypercalcemia of malignancy (HHM), intense osteoclastic bone resorption is principally responsible for the observed hypercalcemia. The effect of the carbonic anhydrase inhibitor acetazolamide on the hypercalcemia induced by the H500 Leydig cell tumor in Fisher rats, a well-described model of HHM,. . . in serum phosphorus, urine calcium, urine phosphorus, or nephrogenous cAMP excretion between the two groups. Acetazolamide and HTs [5-(3-hydroxybenzoyl)-2-thiophenesulfonamide], another carbonic anhydrase inhibitor, both significantly inhibited in vitro bone resorption induced by 5 + 10-9 M 36Tyr(1-36)-PTHrP-amide (PTHrP, parathyroid hormone-related protein). Acetazolamide. . .
ST carbonic anhydrase inhibitor hypercalcemia malignancy
IT Osteoclast
(bone resorption by, carbonic anhydrase inhibitors effect on, in neoplasm)
IT Neoplasm
(hypercalcemia in, carbonic anhydrase inhibitors treatment of, bone resorption response in)
IT Resorption
(of bone, carbonic anhydrase inhibitors effect on, in neoplasm)
IT Bone, metabolism
(resorption of, carbonic anhydrase inhibitors effect on)
IT 59-66-5, Acetazolamide 114891-23-5, 5-(3-Hydroxybenzoyl)-2-thiophenesulfonamide
RL: BIOL (Biological study)
(hypercalcemia treatment with, in neoplasm, bone resorption

response in)
IT 9001-03-0, Carbonic anhydrase
RL: BIOL (Biological study)
(inhibitors of, hypercalcemia treatment with, in neoplasm, bone resorption response in)
IT 7440-70-2, Calcium, biological studies
RL: BIOL (Biological study)
(metabolic disorders, hypercalcemia, treatment of, with carbonic anhydrase inhibitors, in neoplasm)

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AB Antitumor formulations consist of 1-phthalidyl-5-fluoromuracil (I) [81820-68-0] and carbonic anhydrase-inhibiting sulfonamides (R1SO2NR2R3, where R1 = substituted thienyl, thiazolyl, thiadiazolyl, Ph; R2, R3 = H, substituted alkyl, aryl, acyl and Bz). . . I. In Yoshida sarcoma-bearing mice, combined oral administration of I (400 mg/kg/day) and sulfanilamide [63-74-1] (200 mg/kg/day) decreased the relative tumor size from 1.00 in controls to 0.18 compared to only 0.41 when I is administered alone. Thus, tablets were prepared containing I 100, acetazolamide [59-66-5] 10, lactose 200, wheat starch 01, hydroxypropylcellulose 4 and Mg stearate 2 mg.
IT 59-66-5 63-74-1 72-14-0 133-67-5 515-64-0 723-46-6 4563-84-2
RL: BIOL (Biological study)
(antitumor pharmaceuticals containing phthalidylfluorouracil and)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.07	37.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.34	-2.34

STN INTERNATIONAL LOGOFF AT 17:06:42 ON 31 JAN 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  OCT 23   The Derwent World Patents Index suite of databases on STN
                   has been enhanced and reloaded
 NEWS  4  OCT 30   CHEMLIST enhanced with new search and display field
 NEWS  5  NOV 03   JAPIO enhanced with IPC 8 features and functionality
 NEWS  6  NOV 10   CA/CAplus F-Term thesaurus enhanced
 NEWS  7  NOV 10   STN Express with Discover! free maintenance release Version
                   8.01c now available
 NEWS  8  NOV 20   CA/CAplus to MARPAT accession number crossover limit increased
                   to 50,000
 NEWS  9  DEC 01   CAS REGISTRY updated with new ambiguity codes
 NEWS 10  DEC 11   CAS REGISTRY chemical nomenclature enhanced
 NEWS 11  DEC 14   WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 12  DEC 14   GBFULL and FRFULL enhanced with IPC 8 features and
                   functionality
 NEWS 13  DEC 18   CA/CAplus pre-1967 chemical substance index entries enhanced
                   with preparation role
 NEWS 14  DEC 18   CA/CAplus patent kind codes updated
 NEWS 15  DEC 18   MARPAT to CA/CAplus accession number crossover limit increased
                   to 50,000
 NEWS 16  DEC 18   MEDLINE updated in preparation for 2007 reload
 NEWS 17  DEC 27   CA/CAplus enhanced with more pre-1907 records
 NEWS 18  JAN 08   CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 19  JAN 16   CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 20  JAN 16   IPC version 2007.01 thesaurus available on STN
 NEWS 21  JAN 16   WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 22  JAN 22   CA/CAplus updated with revised CAS roles
 NEWS 23  JAN 22   CA/CAplus enhanced with patent applications from India
 NEWS 24  JAN 29   PHAR reloaded with new search and display fields
 NEWS 25  JAN 29   CAS Registry Number crossover limit increased to 300,000 in
                   multiple databases

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:45:08 ON 01 FEB 2007

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
```

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 14:45:17 ON 01 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5
DICTIONARY FILE UPDATES: 31 JAN 2007 HIGHEST RN 918932-71-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10723795_2.str



chain nodes :
1 2 3 4 10 11 12 13 14
ring nodes :
5 6 7 8 9
chain bonds :
1-4 1-2 1-3 4-5 4-14 8-10 10-11 10-12 10-13
ring bonds :
5-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-4 1-2 1-3 4-5 5-6 5-9 6-7 7-8 8-9 8-10 10-11 10-12 10-13
exact bonds :
4-14

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:45:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22 TO 418
PROJECTED ANSWERS: 8 TO 329

L2 8 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:45:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 351 TO ITERATE

100.0% PROCESSED 351 ITERATIONS 218 ANSWERS
SEARCH TIME: 00.00.01

L3 218 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 14:45:53 ON 01 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Feb 2007 VOL 146 ISS 6
FILE LAST UPDATED: 31 Jan 2007 (20070131/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s l3/dgn
          199 L3
        73556 DGN/RL
L4          0 L3/DGN
                (L3 (L) DGN/RL)

=> s l3
L5        199 L3

=> s tumor? or neoplas? or cancer?
       456707 TUMOR?
       479316 NEOPLAS?
       319785 CANCER?
L6     756702 TUMOR? OR NEOPLAS? OR CANCER?

=> s l6 and l5
L7         26 L6 AND L5

=> s l7 not py>2002
      4853307 PY>2002
L8          4 L7 NOT PY>2002

=> d ibib 1-4

L8   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2001:322273  CAPLUS
DOCUMENT NUMBER:         135:55472
TITLE:                   Carbonic anhydrase inhibitors: 88. Sulfonamides as
                         antitumor agents?
AUTHOR(S):               Supuran, Claudiu T.; Briganti, Fabrizio; Tilli,
                         Silvia; Chegwidden, W. Richard; Scozzafava, Andrea
CORPORATE SOURCE:        Laboratorio di Chimica Inorganica e Bioinorganica,
                         Universita degli Studi, Laboratorio di Chimica
                         Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE:                  Bioorganic & Medicinal Chemistry (2001), 9(3), 703-714
                         CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER:               Elsevier Science Ltd.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
OTHER SOURCE(S):         CASREACT 135:55472
REFERENCE COUNT:         81    THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2000:696271  CAPLUS
DOCUMENT NUMBER:         133:344324
TITLE:                   Carbonic anhydrase inhibitors - Part 94.
                         1,3,4-Thiadiazole-2-sulfonamide derivatives as
                         antitumor agents?
AUTHOR(S):               Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE:        Universita degli Studi, Laboratorio di Chimica
```

Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: European Journal of Medicinal Chemistry (2000), 35(9), 867-874
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:379680 CAPLUS
DOCUMENT NUMBER: 133:171930
TITLE: Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV
AUTHOR(S): Scozzafava, Andrea; Supuran, Claudiu T.
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(10), 1117-1120
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:457068 CAPLUS
DOCUMENT NUMBER: 61:57068
ORIGINAL REFERENCE NO.: 61:9923b-e
TITLE: The anticonvulsive action of acetazolamide, its derivatives, and some other sulfonamides
AUTHOR(S): Gores, E.; Hilgetag, G.; Jung, F.
CORPORATE SOURCE: Humboldt Univ., Berlin
SOURCE: Acta Physiologica Academiae Scientiarum Hungaricae (1961), 19, 95-102
From: CZ 1962(6), 2078.
CODEN: APACAB; ISSN: 0001-6756
DOCUMENT TYPE: Journal
LANGUAGE: German

=> d ibib 1-4 abs kwic

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:322273 CAPLUS
DOCUMENT NUMBER: 135:55472
TITLE: Carbonic anhydrase inhibitors: 88. Sulfonamides as antitumor agents?
AUTHOR(S): Supuran, Claudiu T.; Briganti, Fabrizio; Tilli, Silvia; Chegwidden, W. Richard; Scozzafava, Andrea
CORPORATE SOURCE: Laboratorio di Chimica Inorganica e Bioinorganica, Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(3), 703-714
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:55472

AB Novel sulfonamide inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) were prepared by reaction of aromatic or heterocyclic sulfonamides containing amino, imino, or hydrazino moieties with N,N-dialkyldithiocarbamates in the presence of oxidizing agents (sodium hypochlorite or iodine). The N,N-dialkylthiocarbamylsulfenamido-sulfonamides synthesized in this way behaved as strong inhibitors of human CA I and CA II (hCA I and hCA II) and bovine CA IV (bCA IV). For the most active compds., inhibition consts. ranged from 10-8 to 10-9 M (for isoenzymes II and IV). Three of the derivs. belonging to this new class of CA inhibitors were also tested as inhibitors of tumor cell growth in vitro. These sulfonamides showed potent inhibition of growth against several leukemia, non-small cell lung, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. With several cell lines, GI50 values of 10-75 nM were observed The mechanism of antitumor action with the new sulfonamides reported here remains obscure, but may involve inhibition of CA isoenzymes which predominate in tumor cell membranes (CA IX and CA XII), perhaps causing acidification of the intercellular milieu, or inhibition of intracellular isoenzymes which provide bicarbonate for the synthesis of nucleotides and other essential cell components (CA II and CA V). Optimization of these derivs. from the SAR point of view, might lead to the development of effective novel types of anticancer agents.

REFERENCE COUNT: 81 THERE ARE 81 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Novel sulfonamide inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1) were prepared by reaction of aromatic or heterocyclic sulfonamides containing amino, imino, or hydrazino moieties with N,N-dialkyldithiocarbamates in the presence of oxidizing agents (sodium hypochlorite or iodine). The N,N-dialkylthiocarbamylsulfenamido-sulfonamides synthesized in this way behaved as strong inhibitors of human CA I and CA II (hCA I and hCA II) and bovine CA IV (bCA IV). For the most active compds., inhibition consts. ranged from 10-8 to 10-9 M (for isoenzymes II and IV). Three of the derivs. belonging to this new class of CA inhibitors were also tested as inhibitors of tumor cell growth in vitro. These sulfonamides showed potent inhibition of growth against several leukemia, non-small cell lung, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. With several cell lines, GI50 values of 10-75 nM were observed The mechanism of antitumor action with the new sulfonamides reported here remains obscure, but may involve inhibition of CA isoenzymes which predominate in tumor cell membranes (CA IX and CA XII), perhaps causing acidification of the intercellular milieu, or inhibition of intracellular isoenzymes which provide bicarbonate for the synthesis of nucleotides and other essential cell components (CA II and CA V). Optimization of these derivs. from the SAR point of view, might lead to the development of effective novel types of anticancer agents.

IT 63-74-1 98-18-0 121-30-2 138-39-6 547-52-4 654-62-6 2153-13-1
2368-84-5 3306-62-5 3523-95-3 4392-54-5 5250-72-6
14949-00-9 16840-26-9 35303-76-5 53297-68-0 53297-69-1
60154-06-5 86029-46-1 88615-09-2 120280-13-9 216885-22-2
217972-52-6 345970-47-0 345970-48-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
(sulfonamide carbonic anhydrase inhibitors as antitumor agents)

IT 345970-49-2P 345970-50-5P 345970-51-6P 345970-52-7P 345970-53-8P
345970-54-9P 345970-55-0P 345970-56-1P 345970-57-2P 345970-58-3P
345970-59-4P 345970-60-7P 345970-61-8P 345970-62-9P 345970-63-0P
345970-64-1P 345970-65-2P 345970-66-3P 345970-67-4P
345970-68-5P 345970-69-6P 345970-70-9P 345970-71-0P 345970-72-1P
345970-73-2P 345970-74-3P 345970-75-4P 345970-77-6P 345970-79-8P

345970-80-1P 345970-81-2P 345970-82-3P 345970-83-4P 345970-84-5P
345970-85-6P 345970-86-7P 345970-87-8P 345970-88-9P
345970-89-0P 345970-90-3P 345970-91-4P 345970-92-5P
345970-93-6P 345970-94-7P 345970-95-8P 345970-96-9P 345970-97-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(sulfonamide carbonic anhydrase inhibitors as antitumor agents)
IT 90110-89-7 306314-22-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonamide carbonic anhydrase inhibitors as antitumor agents)

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:696271 CAPLUS
DOCUMENT NUMBER: 133:344324
TITLE: Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?
AUTHOR(S): Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: European Journal of Medicinal Chemistry (2000), 35(9), 867-874
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Potent sulfonamide inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), derivs. of 1,3,4-thiadiazole-2-sulfonamide, possessing inhibition consts. in the range of 10-8-10-9 M against isoenzymes II and IV, were shown to act as efficient in vitro tumor cell growth inhibitors with GI50 (molarity of inhibitor producing a 50% inhibition of tumor cell growth) values typically in the range of 0.1-30 μM against several leukemia, non-small cell lung cancer, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. The mechanism of antitumor action with the new sulfonamides reported here is unknown, but it might involve either inhibition of several CA isoenzymes (such as CA IX, CA XII, CA XIV) present predominantly in tumor cell membranes, acidification of the intracellular environment as a consequence of CA inhibition, uncoupling of mitochondria and/or strong CA V inhibition, or a combination of several such mechanisms. Such derivs. might lead to the development of effective novel types of anticancer agents/therapies.
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Potent sulfonamide inhibitors of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), derivs. of 1,3,4-thiadiazole-2-sulfonamide, possessing inhibition consts. in the range of 10-8-10-9 M against isoenzymes II and IV, were shown to act as efficient in vitro tumor cell growth inhibitors with GI50 (molarity of inhibitor producing a 50% inhibition of tumor cell growth) values typically in the range of 0.1-30 μM against several leukemia, non-small cell lung cancer, ovarian, melanoma, colon, CNS, renal, prostate and breast cancer cell lines. The mechanism of antitumor action with the new sulfonamides reported here is unknown, but it might involve either inhibition of several CA isoenzymes (such as CA IX, CA XII, CA XIV) present predominantly in tumor cell membranes, acidification of the intracellular environment as a consequence of CA inhibition, uncoupling of mitochondria and/or strong CA V inhibition, or a combination of several such mechanisms. Such derivs. might lead to the development of effective

novel types of anticancer agents/therapies.

IT 25182-53-0DP, 1,3,4-Thiadiazole-2-sulfonamide, derivs. 86029-44-9P 90110-89-7P 97919-22-7P, CQS 141430-65-1P, E 7010 144462-41-9P 165668-41-7P, E 7070 196512-72-8P 207795-80-0P 207796-05-2P 306314-22-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(carbonic anhydrase inhibitors: 1,3,4-thiadiazole-2-sulfonamide derivs. as antitumor agents)

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:379680 CAPLUS
DOCUMENT NUMBER: 133:171930
TITLE: Carbonic anhydrase inhibitors: synthesis of N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV
AUTHOR(S): Scozzafava, Andrea; Supuran, Claudiu T.
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(10), 1117-1120
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Several aromatic/heterocyclic sulfonamides possessing free amino, imino, or hydrazino moieties were transformed into the corresponding N-morpholylthiocarbonylsulfenyl derivs. by reaction with N-morpholyldithiocarbamate in the presence of oxidizing agents (NaClO or iodine). These compds. showed nanomolar inhibition against three CA (carbonic anhydrase) isoenzymes and interesting in vitro tumor cell growth inhibitory properties against several leukemia, non-small cell lung, ovarian, melanoma, colon, CNS, renal, prostate, and breast cancer cell lines.
REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
AB Several aromatic/heterocyclic sulfonamides possessing free amino, imino, or hydrazino moieties were transformed into the corresponding N-morpholylthiocarbonylsulfenyl derivs. by reaction with N-morpholyldithiocarbamate in the presence of oxidizing agents (NaClO or iodine). These compds. showed nanomolar inhibition against three CA (carbonic anhydrase) isoenzymes and interesting in vitro tumor cell growth inhibitory properties against several leukemia, non-small cell lung, ovarian, melanoma, colon, CNS, renal, prostate, and breast cancer cell lines.
ST morpholylthiocarbonylsulfenylaminosulfonamide inhibition carbonic anhydrase isoenzyme tumor cell growth
IT Antitumor agents
(N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
(central nervous system; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Nervous system
Nervous system
(central, neoplasm, inhibitors; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide

interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Intestine, neoplasm
Intestine, neoplasm
(colon, inhibitors; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
(colon; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Kidney, neoplasm
Kidney, neoplasm
Ovary, neoplasm
Ovary, neoplasm
(inhibitors; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
Antitumor agents
(kidney; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
(leukemia; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
(lung non-small-cell carcinoma; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
(mammary gland; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
(melanoma; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Mammary gland
Mammary gland
Prostate gland
Prostate gland
(neoplasm, inhibitors; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Lung, neoplasm
Lung, neoplasm
(non-small-cell carcinoma, inhibitors; N-morpholylthiocarbonylsulfenyla mino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Enzyme kinetics
(of inhibition; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)
IT Antitumor agents
Antitumor agents
(ovary; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic

sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)

IT Antitumor agents
(prostate gland; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)

IT 288584-57-6 288584-58-7 288584-59-8 288584-60-1 288584-61-2
288584-62-3 288584-63-4 288584-64-5 288584-65-6 288584-66-7
288584-67-8 288584-68-9 288584-69-0 288584-70-3 288584-71-4
288584-72-5 288584-73-6 288584-74-7 288584-75-8
288584-76-9
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)

IT 9001-03-0, Carbonic anhydrase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(isoenzymes; N-morpholylthiocarbonylsulfenylamino aromatic/heterocyclic sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV and cancer growth inhibitory properties)

IT 63-74-1 98-18-0 121-30-2 138-39-6 547-52-4 2368-84-5 3306-62-5
3523-95-3 4392-54-5 5250-72-6 14949-00-9 16840-26-9
35303-76-5 53297-68-0 53297-69-1 60154-06-5 86029-46-1
120280-13-9 216885-22-2 217972-52-6
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonamide interaction with carbonic anhydrase isoenzymes I, II and IV)

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1964:457068 CAPLUS
DOCUMENT NUMBER: 61:57068
ORIGINAL REFERENCE NO.: 61:9923b-e
TITLE: The anticonvulsive action of acetazolamide, its derivatives, and some other sulfonamides
AUTHOR(S): Gores, E.; Hilgetag, G.; Jung, F.
CORPORATE SOURCE: Humboldt Univ., Berlin
SOURCE: Acta Physiologica Academiae Scientiarum Hungaricae (1961), 19, 95-102
From: CZ 1962(6), 2078.
CODEN: APACAB; ISSN: 0001-6756
DOCUMENT TYPE: Journal
LANGUAGE: German

AB The following 2-acetamido- and 5-aminosulfonyl-1,3,4-thiadiazole compds. were tested for convulsion-preventive action against elec., pentamethylenetetrazole, and strychnine convulsions: 2-acetamido-1,3,4-thiadizazole, 5-[ethylaminosulfonyl]- (I); 5-(diethylaminosulfonyl)- (II); 5-(ureidosulfonyl)- (III); 5-[N2-methylureidosulfonyl)- (IV); 5-(N2-ethylureidosulfonyl)- (V); 5-(N2-butylureidosulfonyl)- (VI); and 5-(N2-phenylureidosulfonyl)-; 5-aminosulfonyl-1,3,4-thiadiazole; 2-amino-(VII); 2-acetamido-(VIII); 2-(p-chlorobenzenesulfonamido)- (IX); 2-(p-carboxybenzenesulfonamido)-; 2-(p-nitrobenzenesulfonamido)-; and 2-(2-acetamido-1,3,4-thiadiazole-5-sulfonamido)-. The following compds. were also investigated: 2,2'-succinyldiaminobis(1,3,4-thiadiazole-5-sulfonamide) (X); N,N'-hexamethylenebis[3-(2-acetamido-1,3,4-thiadiazol-5-ylsulfonyl)urea]; N',N'-octamethylenebis[3-(2-acetamido-1,3,4-thiadiazol-5-ylsulfonyl)urea]; p-acetamidobenzenesulfonamide (XI); oranil; orabet;

Prontosil; Uliron C; Neo-Uliron; p-(p-chlorobenzenesulfonylamino)benzenesu
lfonamide; 1,4-benzenedisulfonamide; chlorothiazide; dihydrochlorothiazide;
and triazurol. III, V-XI, and XIII were effective against elec.
convulsions; only II was effective against pentamethylenetetrazole
convulsions; and I, IV, XII, and XIII were effective against strychnine
convulsions. A parallel with the diuretic action was not established.
IT 58-93-5, 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-,
1,1-dioxide 58-94-6, 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-,
1,1-dioxide 64-77-7, Urea, 1-butyl-3-(p-tolylsulfonyl)- 103-12-8,
Benzenesulfonamide, p-(2,4-diaminophenyl)azo]- 121-61-9, Acetanilide,
4'-sulfamoyl- 339-43-5, Urea, 1-butyl-3-sulfanilyl- 500-42-5,
s-Triazine, 2-amino-4-(p-chloroanilino)- 547-52-4, Sulfanilanilide,
4'-sulfamoyl- 547-53-5, Sulfanilanilide, 4'-(methylsulfamoyl)-
10518-52-2, Urea, 1-[(5-acetamido-1,3,4-thiadiazol-2-yl)sulfonyl]-3-butyl-
13463-26-8, 1,3,4-Thiadiazole-2-sulfonamide, 5-(p-
chlorobenzenesulfonamido)- 13681-31-7, 1,3,4-Thiadiazole-2-sulfonamide,
5-acetamido-N,N-diethyl- 14949-00-9, 1,3,4-Thiadiazole-2-sulfonamide,
5-amino- 16993-45-6, p-Benzenedisulfonamide 25182-53-0,
1,3,4-Thiadiazole-2-sulfonamide, 5-acetamido 84884-65-1, Urea,
[(5-acetamido-1,3,4-thiadiazol-2-yl)sulfonyl]- 84884-66-2, Urea,
1-[(5-acetamido-1,3,4-thiadiazol-2-yl)sulfonyl]-3-methyl- 84884-70-8,
Urea, 1-[(5-acetamido-1,3,4-thiadiazol-2-yl)sulfonyl]-3-phenyl-
89489-04-3, 1,3,4-Thiadiazole-2-sulfonamide, 5-acetamido-N-ethyl-
90110-89-7, 1,3,4-Thiadiazole-2-sulfonamide, 5-(p-
nitrobenzenesulfonamido)- 90271-63-9, Urea, 1-[(5-acetamido-1,3,4-
thiadiazol-2-yl)sulfonyl]-3-ethyl- 90324-21-3, Benzoic acid,
p-[(5-sulfamoyl-1,3,4-thiadiazol-2-yl)sulfamoyl]- 91114-64-6,
N,5'-Bi[1,3,4-thiadiazole-2-sulfonamide], 5-acetamido- 91398-32-2,
Benzenesulfonanilide, 4-chloro-4'-sulfamoyl- 92187-74-1, Succinamide,
N,N'-bis(5-sulfamoyl-1,3,4-thiadiazol-2-yl)- 97790-65-3, Urea,
1,1'-hexamethylenebis[3-[(5-acetamido-1,3,4-thiadiazol-2-yl)sulfonyl]-
98766-55-3, Urea, 1,1'-octamethylenebis[3-[(5-acetamido-1,3,4-thiadiazol-2-
yl)sulfonyl]-
(as anticonvulsant)
IT 26367-45-3, Alanine, 3-[p-[bis(2-chloroethyl)amino]phenyl]-N-formyl-
(neoplasm inhibition by)

=> (positron emission tomography) or PET
(POSITRON IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s (positron emission tomography) or PET
58520 POSITRON
12716 POSITRONS
60849 POSITRON
(POSITRON OR POSITRONS)
506316 EMISSION
93434 EMISSIONS
550703 EMISSION
(EMISSION OR EMISSIONS)
18466 TOMOGRAPHY
10 TOMOGRAPHIES
18471 TOMOGRAPHY
(TOMOGRAPHY OR TOMOGRAPHIES)
23557 TOMOG
31 TOMOGS
23568 TOMOG
(TOMOG OR TOMOGS)
29235 TOMOGRAPHY

```
                (TOMOGRAPHY OR TOMOG)
          9739 POSITRON EMISSION TOMOGRAPHY
                (POSITRON(W)EMISSION(W)TOMOGRAPHY)
         67172 PET
           967 PETS
         67621 PET
                (PET OR PETS)
L9       70632 (POSITRON EMISSION TOMOGRAPHY) OR PET

=> d his

     (FILE 'HOME' ENTERED AT 14:45:08 ON 01 FEB 2007)

     FILE 'REGISTRY' ENTERED AT 14:45:17 ON 01 FEB 2007
L1              STRUCTURE UPLOADED
L2            8 S L1
L3          218 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:45:53 ON 01 FEB 2007
L4            0 S L3/DGN
L5          199 S L3
L6       756702 S TUMOR? OR NEOPLAS? OR CANCER?
L7           26 S L6 AND L5
L8            4 S L7 NOT PY>2002
L9        70632 S (POSITRON EMISSION TOMOGRAPHY) OR PET

=> s l9 (L) l6
L10       3607 L9 (L) L6

=> s l10 not py>2002
       4853307 PY>2002
L11       2179 L10 NOT PY>2002

=> d ibib abs kwic

L11  ANSWER 1 OF 2179  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:990937  CAPLUS
DOCUMENT NUMBER:         145:484479
TITLE:                   Protein and cDNA sequences of a 24.09-kilodalton human
                         proteasome subunit HC5 sequence homolog and their
                         therapeutic uses
INVENTOR(S):             Mao, Yumin; Xie, Yi
PATENT ASSIGNEE(S):      Shanghai Biowindow Gene Development, Inc., Peop. Rep.
                         China
SOURCE:                  Faming Zhuanli Shenqing Gongkai Shuomingshu, 31pp.
                         CODEN: CNXXEV
DOCUMENT TYPE:           Patent
LANGUAGE:                Chinese
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
     CN 1345865           A     20020424    CN 2000-125585         20000929
PRIORITY APPLN. INFO.:                      CN 2000-125585         20000929
AB   The invention provides the protein and cDNA sequences of a novel
     24.09-kilodalton human protein, designated as "proteasome subunit HC5
     24.09", which has sequence homol. with known proteasome subunit HC5.  The
     invention relates to expression of proteasome subunit HC5 sequence homolog
     in E. coli BL21(DE3)plySs transfected with plasmid pET-28(+).
     The invention also relates to preparation of antibody against proteasome
     subunit HC5 sequence homolog.  The invention further relates to the uses
```

of the proteasome subunit HC5 sequence homolog in treatment of proteasome subunit HC5-related diseases (such as tumor, diabetes mellitus, menstrual disorder, peptic ulcer, arrhythmia, anemia, and epilepsy).

AB The invention provides the protein and cDNA sequences of a novel 24.09-kilodalton human protein, designated as "proteasome subunit HC5 24.09", which has sequence homol. with known proteasome subunit HC5. The invention relates to expression of proteasome subunit HC5 sequence homolog in E. coli BL21(DE3)plySs transfected with plasmid pET-28(+). The invention also relates to preparation of antibody against proteasome subunit HC5 sequence homolog. The invention further relates to the uses of the proteasome subunit HC5 sequence homolog in treatment of proteasome subunit HC5-related diseases (such as tumor, diabetes mellitus, menstrual disorder, peptic ulcer, arrhythmia, anemia, and epilepsy).

```
=> s (positron emission tomography)
         58520 POSITRON
         12716 POSITRONS
         60849 POSITRON
                 (POSITRON OR POSITRONS)
        506316 EMISSION
         93434 EMISSIONS
        550703 EMISSION
                 (EMISSION OR EMISSIONS)
         18466 TOMOGRAPHY
            10 TOMOGRAPHIES
         18471 TOMOGRAPHY
                 (TOMOGRAPHY OR TOMOGRAPHIES)
         23557 TOMOG
            31 TOMOGS
         23568 TOMOG
                 (TOMOG OR TOMOGS)
         29235 TOMOGRAPHY
                 (TOMOGRAPHY OR TOMOG)
L12       9739 (POSITRON EMISSION TOMOGRAPHY)
                 (POSITRON(W)EMISSION(W)TOMOGRAPHY)

=> s l12 (L) l6
L13       1718 L12 (L) L6

=> d ibib kwic

L13  ANSWER 1 OF 1718  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2007:101979  CAPLUS
TITLE:                   In vivo biodistribution and highly efficient tumour
                         targeting of carbon nanotubes in mice
AUTHOR(S):               Liu, Zhuang; Cai, Weibo; He, Lina; Nakayama, Nozomi;
                         Chen, Kai; Sun, Xiaoming; Chen, Xiaoyuan; Dai, Hongjie
CORPORATE SOURCE:        Department of Chemistry, Stanford University,
                         Stanford, CA, 94305, USA
SOURCE:                  Nature Nanotechnology (2007), 2(1), 47-52
                         CODEN: NNAABX; ISSN: 1748-3387
PUBLISHER:               Nature Publishing Group
DOCUMENT TYPE:           Journal
LANGUAGE:                English
```

AB Single-walled carbon nanotubes (SWNTs) exhibit unique size, shape and phys. properties that make them promising candidates for biol. applications. Here, we investigate the biodistribution of radio-labeled SWNTs in mice by in vivo positron emission tomog. (PET), ex vivo biodistribution and Raman spectroscopy. It is found that SWNTs that are functionalized with phospholipids bearing polyethylene-glycol (PEG) are surprisingly stable in vivo. The effect of

PEG chain length on the biodistribution and circulation of the SWNTs is studied. Effectively PEGylated SWNTs exhibit relatively long blood circulation times and low uptake by the reticuloendothelial system (RES). Efficient targeting of integrin pos. tumor in mice is achieved with SWNTs coated with PEG chains linked to an arginine-glycine-aspartic acid (RGD) peptide. A high tumor accumulation is attributed to the multivalent effect of the SWNTs. The Raman signatures of SWNTs are used to directly probe the presence of nanotubes in mice tissues and confirm the radio-label-based results.

```
=> s brain and l13
        538747 BRAIN
         25015 BRAINS
        541541 BRAIN
                 (BRAIN OR BRAINS)
L14        297 BRAIN AND L13

=> s carbonic
         44315 CARBONIC
             1 CARBONICS
L15      44316 CARBONIC
                 (CARBONIC OR CARBONICS)

=> s l15 and l14
L16          0 L15 AND L14

=> s l14 not py>2003
       3800069 PY>2003
L17        213 L14 NOT PY>2003

=> s l14 not py>2002
       4853307 PY>2002
L18        193 L14 NOT PY>2002

=> d ibib abs kwic

L18  ANSWER 1 OF 193  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2004:7237  CAPLUS
DOCUMENT NUMBER:         141:319962
TITLE:                   Preparation 18F-choline analogue and its
                         biodistribution in annuals
AUTHOR(S):               Tang, Ganghua; Tang, Xiaolan; Wang, Mingfang; Zhang,
                         Lan; Li, Zhi; Luo, Lei; Huang, Zuhan
CORPORATE SOURCE:        Nanfang PET Center, Nanfang Hospital, First Military
                         Medical University, Guangzhou, 510515, Peop. Rep.
                         China
SOURCE:                  Zhonghua Heyixue Zazhi (2002), 22(3), 172-174
                         CODEN: CITCDE; ISSN: 0253-9780
PUBLISHER:               Jiangsusheng Yuanzi Yixue Yanjiuso
DOCUMENT TYPE:           Journal
LANGUAGE:                Chinese
```

AB A 18F labeled choline analog, 2-18F- fluoroethyl-dimethyl 2-oxyethyl-ammonium (FECH), a tumor imaging agent, was developed. FECH was prepared via two steps displacement reaction of 18F-fluoride with 1,2-bis(tosyloxy)ethane to give the intermediate, 1-18F-fluoro-2-(tosyloxy) ethane, which was then coupled with dimethylethanolamine to prepare FECH. Radiochem. purity and biodistributions in normal mice and nude mice bearing cancer cell were determined FECH was synthesized in about 25% radiochem. yield with decay-correction and more than 99% radiochem. purity with a total radiosynthesis time of 80 min. Biodistributions of FECH in normal mice and nude mice were as follows: rapid blood clearance;

high uptake in the liver, kidney, bladder and pancreas; low uptake in the brain, myocardium, stomach, intestine and bone; high in tumors in blood, brain, heart, stomach, and muscle. A simple and practical synthesis protocol for FECH is achieved. Biodistribution of FECH in mice is very similar to that of 11C choline reported in literatures, FECH is promising to be an agent in diagnosis of tumors with PET imaging.

AB A 18F labeled choline analog, 2-18F- fluoroethyl-dimethyl 2-oxyethyl-ammonium (FECH), a tumor imaging agent, was developed. FECH was prepared via two steps displacement reaction of 18F-fluoride with 1,2-bis(tosyloxy)ethane to give the intermediate, 1-18F-fluoro-2-(tosyloxy) ethane, which was then coupled with dimethylethanolamine to prepare FECH. Radiochem. purity and biodistributions in normal mice and nude mice bearing cancer cell were determined FECH was synthesized in about 25% radiochem. yield with decay-correction and more than 99% radiochem. purity with a total radiosynthesis time of 80 min. Biodistributions of FECH in normal mice and nude mice were as follows: rapid blood clearance; high uptake in the liver, kidney, bladder and pancreas; low uptake in the brain, myocardium, stomach, intestine and bone; high in tumors in blood, brain, heart, stomach, and muscle. A simple and practical synthesis protocol for FECH is achieved. Biodistribution of FECH in mice is very similar to that of 11C choline reported in literatures, FECH is promising to be an agent in diagnosis of tumors with PET imaging.

IT Imaging agents
Positron-emission tomography
(preparation of 18F-choline analog as tumor imaging agents and its biodistribution in animals and)

=> dhis
DHIS IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 14:45:08 ON 01 FEB 2007)

FILE 'REGISTRY' ENTERED AT 14:45:17 ON 01 FEB 2007
L1 STRUCTURE UPLOADED
L2 8 S L1
L3 218 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:45:53 ON 01 FEB 2007
L4 0 S L3/DGN
L5 199 S L3
L6 756702 S TUMOR? OR NEOPLAS? OR CANCER?
L7 26 S L6 AND L5
L8 4 S L7 NOT PY>2002
L9 70632 S (POSITRON EMISSION TOMOGRAPHY) OR PET
L10 3607 S L9 (L) L6
L11 2179 S L10 NOT PY>2002
L12 9739 S (POSITRON EMISSION TOMOGRAPHY)
L13 1718 S L12 (L) L6
L14 297 S BRAIN AND L13
L15 44316 S CARBONIC
L16 0 S L15 AND L14
L17 213 S L14 NOT PY>2003
L18 193 S L14 NOT PY>2002

```
=> s l5 and l12
L19          3 L5 AND L12

=> d ibib 1-3

L19  ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:1354320  CAPLUS
DOCUMENT NUMBER:         146:100561
TITLE:                   Preparation of arenesulfonamide fluorescent dye
                         conjugates having carbonic anhydrase inhibiting
                         activity and their use as therapeutic and diagnostic
                         agents
INVENTOR(S):             Supuran, Claudiu; Scozzafava, Andrea
PATENT ASSIGNEE(S):      Italy
SOURCE:                  PCT Int. Appl., 46pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     WO 2006137009        A2    20061228    WO 2006-IB51976         20060620
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
             SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,
             US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     WO 2006137092        A1    20061228    WO 2005-IT366           20050623
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
             KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       WO 2005-IT366       A  20050623

L19  ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2006:1354145  CAPLUS
DOCUMENT NUMBER:         146:100560
TITLE:                   Preparation of fluorescent sulfonamide derivatives
                         having carbonic anhydrase inhibiting activity and
                         their use as cancer therapeutic and diagnostic agents
INVENTOR(S):             Supuran, Claudiu T.; Scozzafava, Andrea
PATENT ASSIGNEE(S):      Italy
SOURCE:                  PCT Int. Appl., 43pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
```

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006137092	A1	20061228	WO 2005-IT366	20050623

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

WO 2006137009	A2	20061228	WO 2006-IB51976	20060620

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2005-IT366 A 20050623
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:687761 CAPLUS
DOCUMENT NUMBER: 130:52370
TITLE: Carbonic anhydrase inhibitors - Part 29: interaction of isoenzymes I, II and IV with benzolamide-like derivatives
AUTHOR(S): Supuran, Claudiu T.; Ilies, Marc A.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Dipartimento di Chimica, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, 50121, Italy
SOURCE: European Journal of Medicinal Chemistry (1998), 33(9), 739-751
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Editions Scientifiques et Medicales Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:45:08 ON 01 FEB 2007)

FILE 'REGISTRY' ENTERED AT 14:45:17 ON 01 FEB 2007

```
L1              STRUCTURE UPLOADED
L2            8 S L1
L3          218 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 14:45:53 ON 01 FEB 2007
L4            0 S L3/DGN
L5          199 S L3
L6       756702 S TUMOR? OR NEOPLAS? OR CANCER?
L7           26 S L6 AND L5
L8            4 S L7 NOT PY>2002
L9        70632 S (POSITRON EMISSION TOMOGRAPHY) OR PET
L10        3607 S L9 (L) L6
L11        2179 S L10 NOT PY>2002
L12        9739 S (POSITRON EMISSION TOMOGRAPHY)
L13        1718 S L12 (L) L6
L14         297 S BRAIN AND L13
L15       44316 S CARBONIC
L16           0 S L15 AND L14
L17         213 S L14 NOT PY>2003
L18         193 S L14 NOT PY>2002
L19           3 S L5 AND L12

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      71.93     244.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -5.46      -5.46

STN INTERNATIONAL LOGOFF AT 14:56:05 ON 01 FEB 2007



Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
```

```
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  OCT 23  The Derwent World Patents Index suite of databases on STN
                  has been enhanced and reloaded
 NEWS  4  OCT 30  CHEMLIST enhanced with new search and display field
 NEWS  5  NOV 03  JAPIO enhanced with IPC 8 features and functionality
 NEWS  6  NOV 10  CA/CAplus F-Term thesaurus enhanced
 NEWS  7  NOV 10  STN Express with Discover! free maintenance release Version
                  8.01c now available
 NEWS  8  NOV 20  CA/CAplus to MARPAT accession number crossover limit increased
                  to 50,000
 NEWS  9  DEC 01  CAS REGISTRY updated with new ambiguity codes
 NEWS 10  DEC 11  CAS REGISTRY chemical nomenclature enhanced
 NEWS 11  DEC 14  WPIDS/WPINDEX/WPIX manual codes updated
 NEWS 12  DEC 14  GBFULL and FRFULL enhanced with IPC 8 features and
                  functionality
 NEWS 13  DEC 18  CA/CAplus pre-1967 chemical substance index entries enhanced
                  with preparation role
 NEWS 14  DEC 18  CA/CAplus patent kind codes updated
 NEWS 15  DEC 18  MARPAT to CA/CAplus accession number crossover limit increased
                  to 50,000
 NEWS 16  DEC 18  MEDLINE updated in preparation for 2007 reload
 NEWS 17  DEC 27  CA/CAplus enhanced with more pre-1907 records
 NEWS 18  JAN 08  CHEMLIST enhanced with New Zealand Inventory of Chemicals
 NEWS 19  JAN 16  CA/CAplus Company Name Thesaurus enhanced and reloaded
 NEWS 20  JAN 16  IPC version 2007.01 thesaurus available on STN
 NEWS 21  JAN 16  WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
 NEWS 22  JAN 22  CA/CAplus updated with revised CAS roles
 NEWS 23  JAN 22  CA/CAplus enhanced with patent applications from India
 NEWS 24  JAN 29  PHAR reloaded with new search and display fields
 NEWS 25  JAN 29  CAS Registry Number crossover limit increased to 300,000 in
                  multiple databases

 NEWS EXPRESS  NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:02:04 ON 05 FEB 2007

=>
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x
```

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	27	AUG 27	USPATOLD now available on STN
NEWS	28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:53:57 ON 28 AUG 2007

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'CAPLUS' ENTERED AT 07:54:12 ON 28 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Aug 2007 VOL 147 ISS 10
FILE LAST UPDATED: 27 Aug 2007 (20070827/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s us 20040146955/pn
L1   1 US 20040146955/PN
                (US2004146955/PN)

=> sel rn
E1 THROUGH E108 ASSIGNED

=> file reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                             ENTRY   SESSION
FULL ESTIMATED COST   2.56   2.77

FILE 'REGISTRY' ENTERED AT 07:54:29 ON 28 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 AUG 2007 HIGHEST RN 945649-99-0
DICTIONARY FILE UPDATES: 27 AUG 2007 HIGHEST RN 945649-99-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and

predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s e1-e108
             1 138-39-6/BI
               (138-39-6/RN)
             1 3523-95-3/BI
               (3523-95-3/RN)
             1 35303-76-5/BI
               (35303-76-5/RN)
             1 63-74-1/BI
               (63-74-1/RN)
             1 120-97-8/BI
               (120-97-8/RN)
             1 120279-96-1/BI
               (120279-96-1/RN)
             1 121-30-2/BI
               (121-30-2/RN)
             1 138-41-0/BI
               (138-41-0/RN)
             1 138890-62-7/BI
               (138890-62-7/RN)
             1 14949-00-9/BI
               (14949-00-9/RN)
             1 165668-41-7/BI
               (165668-41-7/RN)
             1 2153-13-1/BI
               (2153-13-1/RN)
             1 215998-40-6/BI
               (215998-40-6/RN)
             1 215998-42-8/BI
               (215998-42-8/RN)
             1 215998-44-0/BI
               (215998-44-0/RN)
             1 215998-46-2/BI
               (215998-46-2/RN)
             1 215998-48-4/BI
               (215998-48-4/RN)
             1 215998-50-8/BI
               (215998-50-8/RN)
             1 215998-52-0/BI
               (215998-52-0/RN)
             1 215998-54-2/BI
               (215998-54-2/RN)
             1 215998-56-4/BI
               (215998-56-4/RN)
             1 215998-58-6/BI
               (215998-58-6/RN)
             1 215998-60-0/BI
               (215998-60-0/RN)
             1 215998-62-2/BI
               (215998-62-2/RN)
             1 215998-64-4/BI
               (215998-64-4/RN)
             1 215998-66-6/BI
               (215998-66-6/RN)
             1 215998-68-8/BI
               (215998-68-8/RN)
             1 215998-70-2/BI

(215998-70-2/RN)
1 215998-72-4/BI
(215998-72-4/RN)
1 215998-74-6/BI
(215998-74-6/RN)
1 215998-76-8/BI
(215998-76-8/RN)
1 215998-78-0/BI
(215998-78-0/RN)
1 215998-80-4/BI
(215998-80-4/RN)
1 215998-82-6/BI
(215998-82-6/RN)
1 215998-84-8/BI
(215998-84-8/RN)
1 215998-86-0/BI
(215998-86-0/RN)
1 215998-88-2/BI
(215998-88-2/RN)
1 215998-90-6/BI
(215998-90-6/RN)
1 215998-92-8/BI
(215998-92-8/RN)
1 215998-94-0/BI
(215998-94-0/RN)
1 215998-96-2/BI
(215998-96-2/RN)
1 215998-98-4/BI
(215998-98-4/RN)
1 215999-00-1/BI
(215999-00-1/RN)
1 215999-02-3/BI
(215999-02-3/RN)
1 215999-04-5/BI
(215999-04-5/RN)
1 215999-06-7/BI
(215999-06-7/RN)
1 215999-08-9/BI
(215999-08-9/RN)
1 215999-10-3/BI
(215999-10-3/RN)
1 215999-12-5/BI
(215999-12-5/RN)
1 215999-14-7/BI
(215999-14-7/RN)
1 215999-16-9/BI
(215999-16-9/RN)
1 215999-18-1/BI
(215999-18-1/RN)
1 216885-10-8/BI
(216885-10-8/RN)
1 2368-84-5/BI
(2368-84-5/RN)
1 244122-00-7/BI
(244122-00-7/RN)
1 259131-75-4/BI
(259131-75-4/RN)
1 29927-14-8/BI
(29927-14-8/RN)
1 3306-62-5/BI
(3306-62-5/RN)
1 345970-47-0/BI

(345970-47-0/RN)
1 345970-48-1/BI
(345970-48-1/RN)
1 35203-91-9/BI
(35203-91-9/RN)
1 4392-54-5/BI
(4392-54-5/RN)
1 452-35-7/BI
(452-35-7/RN)
1 53297-68-0/BI
(53297-68-0/RN)
1 53297-69-1/BI
(53297-69-1/RN)
1 547-52-4/BI
(547-52-4/RN)
1 554-57-4/BI
(554-57-4/RN)
1 59-66-5/BI
(59-66-5/RN)
1 60154-06-5/BI
(60154-06-5/RN)
1 606-25-7/BI
(606-25-7/RN)
1 654-62-6/BI
(654-62-6/RN)
1 67472-44-0/BI
(67472-44-0/RN)
1 688805-64-3/BI
(688805-64-3/RN)
1 688805-66-5/BI
(688805-66-5/RN)
1 688805-68-7/BI
(688805-68-7/RN)
1 688805-70-1/BI
(688805-70-1/RN)
1 688805-72-3/BI
(688805-72-3/RN)
1 688805-74-5/BI
(688805-74-5/RN)
1 688805-76-7/BI
(688805-76-7/RN)
1 688805-78-9/BI
(688805-78-9/RN)
1 688805-80-3/BI
(688805-80-3/RN)
1 688805-82-5/BI
(688805-82-5/RN)
1 688805-84-7/BI
(688805-84-7/RN)
1 688805-86-9/BI
(688805-86-9/RN)
1 688805-87-0/BI
(688805-87-0/RN)
1 688805-89-2/BI
(688805-89-2/RN)
1 688805-91-6/BI
(688805-91-6/RN)
1 688805-93-8/BI
(688805-93-8/RN)
1 688805-97-2/BI
(688805-97-2/RN)
1 688805-99-4/BI

```
                (688805-99-4/RN)
            1 688806-01-1/BI
                (688806-01-1/RN)
            1 700378-86-5/BI
                (700378-86-5/RN)
            1 78160-85-7/BI
                (78160-85-7/RN)
            1 78160-87-9/BI
                (78160-87-9/RN)
            1 79783-03-2/BI
                (79783-03-2/RN)
            1 829-71-0/BI
                (829-71-0/RN)
            1 83439-56-9/BI
                (83439-56-9/RN)
            1 86029-46-1/BI
                (86029-46-1/RN)
            1 878502-00-2/BI
                (878502-00-2/RN)
            1 878502-01-3/BI
                (878502-01-3/RN)
            1 878502-02-4/BI
                (878502-02-4/RN)
            1 878502-03-5/BI
                (878502-03-5/RN)
            1 878502-04-6/BI
                (878502-04-6/RN)
            1 878502-05-7/BI
                (878502-05-7/RN)
            1 878502-06-8/BI
                (878502-06-8/RN)
            1 88615-09-2/BI
                (88615-09-2/RN)
            1 9001-03-0/BI
                (9001-03-0/RN)
            1 98-18-0/BI
                (98-18-0/RN)
L2        108 (138-39-6/BI OR 3523-95-3/BI OR 35303-76-5/BI OR 63-74-1/BI OR
                120-97-8/BI OR 120279-96-1/BI OR 121-30-2/BI OR 138-41-0/BI OR
               138890-62-7/BI OR 14949-00-9/BI OR 165668-41-7/BI OR 2153-13-1/BI
                OR 215998-40-6/BI OR 215998-42-8/BI OR 215998-44-0/BI OR 215998-
               46-2/BI OR 215998-48-4/BI OR 215998-50-8/BI OR 215998-52-0/BI OR
               215998-54-2/BI OR 215998-56-4/BI OR 215998-58-6/BI OR 215998-60-0
               /BI OR 215998-62-2/BI OR 215998-64-4/BI OR 215998-66-6/BI OR
               215998-68-8/BI OR 215998-70-2/BI OR 215998-72-4/BI OR 215998-74-6
               /BI OR 215998-76-8/BI OR 215998-78-0/BI OR 215998-80-4/BI OR
               215998-82-6/BI OR 215998-84-8/BI OR 215998-86-0/BI OR 215998-88-2
               /BI OR 215998-90-6/BI OR 215998-92-8/BI OR 215998-94-0/BI OR
               215998-96-2/BI OR 215998-98-4/BI OR 215999-00-1/BI OR 215999-02-3
               /BI OR 215999-04-5/BI OR 215999-06-7/BI OR 215999-08-9/BI OR
               215999-10-3/BI OR 215999-12-5/BI OR 215999-14-7/BI OR 215999-16-9
               /BI OR 215999-18-1/BI OR 216885-10-8/BI OR 2368-84-5/BI OR 244122
               -00-7/BI OR 259131-75-4/BI OR 2992

=> file caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   0.45       3.22

FILE 'CAPLUS' ENTERED AT 07:54:49 ON 28 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

FILE COVERS 1907 - 28 Aug 2007 VOL 147 ISS 10
FILE LAST UPDATED: 27 Aug 2007 (20070827/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> d his

     (FILE 'HOME' ENTERED AT 07:53:57 ON 28 AUG 2007)

     FILE 'CAPLUS' ENTERED AT 07:54:12 ON 28 AUG 2007
L1             1 S US 20040146955/PN
                 SEL RN

     FILE 'REGISTRY' ENTERED AT 07:54:29 ON 28 AUG 2007
L2           108 S E1-E108

     FILE 'CAPLUS' ENTERED AT 07:54:49 ON 28 AUG 2007

=> s l2
L3       23381 L2

=> s l2/biol
         23381 L2
       7024327 BIOL/RL
L4       10414 L2/BIOL
                 (L2 (L) BIOL/RL)

=> s cancer? or tumor? or neoplas?
        343513 CANCER?
        481852 TUMOR?
        507305 NEOPLAS?
L5      799250 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 and l5
L6         909 L4 AND L5

=> s diag?
L7      553334 DIAG?

=> s l7 (L) l5
L8       57089 L7 (L) L5

=> s l8 and l4
L9         181 L8 AND L4

=> s l9 not py>2002
```

```
       5672540 PY>2002
L10          23 L9 NOT PY>2002

=> d ibib 1-10

L10  ANSWER 1 OF 23  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2002:942244  CAPLUS
DOCUMENT NUMBER:         138:151256
TITLE:                   Pimonidazole binding and tumor vascularity predict for
                         treatment outcome in head and neck cancer
AUTHOR(S):               Kaanders, Johannes H. A. M.; Wijffels, Karien I. E.
                         M.; Marres, Henri A. M.; Ljungkvist, Anna S. E.; Pop,
                         Lucas A. M.; Van den Hoogen, Franciscus J. A.; De
                         Wilde, Peter C. M.; Bussink, Johan; Raleigh, James A.;
                         Van der Kogel, Albert J.
CORPORATE SOURCE:        Department of Radiation Oncology, University Medical
                         Center Nijmegen, Nijmegen, 6500 HB, Neth.
SOURCE:                  Cancer Research (2002), 62(23), 7066-7074
                         CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER:               American Association for Cancer Research
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         38    THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 2 OF 23  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2002:579681  CAPLUS
DOCUMENT NUMBER:         138:167618
TITLE:                   Differential gene expression in renal-cell cancer
AUTHOR(S):               Skubitz, Keith M.; Skubitz, Amy P. N.
CORPORATE SOURCE:        Departments of Medicine and Laboratory Medicine and
                         Pathology, University of Minnesota Medical School,
                         Minneapolis, MN, USA
SOURCE:                  Journal of Laboratory and Clinical Medicine (2002),
                         140(1), 52-64
                         CODEN: JLCMAK; ISSN: 0022-2143
PUBLISHER:               Mosby, Inc.
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         35    THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10  ANSWER 3 OF 23  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2002:510395  CAPLUS
DOCUMENT NUMBER:         138:104572
TITLE:                   Molecular determinants of human uveal melanoma
                         invasion and metastasis
AUTHOR(S):               Seftor, Elisabeth A.; Meltzer, Paul S.; Kirschmann,
                         Dawn A.; Pe'er, Jacob; Maniotis, Andrew J.; Trent,
                         Jeffrey M.; Folberg, Robert; Hendrix, Mary J. C.
CORPORATE SOURCE:        Department of Anatomy and Cell Biology, College of
                         Medicine and The Holden Comprehensive Cancer Center,
                         University of Iowa, Iowa City, IA, USA
SOURCE:                  Clinical & Experimental Metastasis (2002), 19(3),
                         233-246
                         CODEN: CEXMD2; ISSN: 0262-0898
PUBLISHER:               Kluwer Academic Publishers
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         70    THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
```

L10 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:506032 CAPLUS
DOCUMENT NUMBER: 137:199256
TITLE: HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron
AUTHOR(S): Mandriota, Stefano J.; Turner, Kevin J.; Davies, David R.; Murray, Paul G.; Morgan, Neil V.; Sowter, Heidi M.; Wykoff, Charles C.; Maher, Eamonn R.; Harris, Adrian L.; Ratcliffe, Peter J.; Maxwell, Patrick H.
CORPORATE SOURCE: Wellcome Trust Centre for Human Genetics, Oxford, OX3 7BN, UK
SOURCE: Cancer Cell (2002), 1(5), 459-468
CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:743200 CAPLUS
DOCUMENT NUMBER: 136:35588
TITLE: Secreted and cell surface genes expressed in benign and malignant colorectal tumors
AUTHOR(S): Buckhaults, Phillip; Rago, Carlo; St. Croix, Brad; Romans, Katharine E.; Saha, Saurabh; Zhang, Lin; Vogelstein, Bert; Kinzler, Kenneth W.
CORPORATE SOURCE: Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA
SOURCE: Cancer Research (2001), 61(19), 6996-7001
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:584391 CAPLUS
DOCUMENT NUMBER: 135:286595
TITLE: Genetic analysis of early- versus late-stage ovarian tumors
AUTHOR(S): Shridhar, Viji; Lee, John; Pandita, Ajay; Iturria, Steve; Avula, Rajeswari; Staub, Julie; Morrissey, Mike; Calhoun, Eric; Sen, Ami; Kalli, Kimberly; Keeney, Gary; Roche, Patrick; Cliby, William; Lu, Karen; Schmandt, Rosemarie; Mills, Gordon B.; Bast, Robert C., Jr.; James, C. David; Couch, Fergus J.; Hartmann, Lynn C.; Lillie, Jim; Smith, David I.
CORPORATE SOURCE: Departments of Experimental Pathology, Division of Laboratory Medicine, The Mayo Clinic, Rochester, MN, 55905, USA
SOURCE: Cancer Research (2001), 61(15), 5895-5904
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:361504 CAPLUS
DOCUMENT NUMBER: 135:146678
TITLE: Carbonic anhydrase inhibitors
AUTHOR(S): Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2001), 1(1), 61-97
CODEN: CMCIC8; ISSN: 1568-0134
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:320060 CAPLUS
DOCUMENT NUMBER: 134:339179
TITLE: Nucleic acids and proteins associated with cancer as antitumor targets
INVENTOR(S): Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001030964	A2	20010503	WO 2000-US29126		20001020
WO 2001030964	A3	20010809			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 2001013397	A	20010508	AU 2001-13397		20001020
PRIORITY APPLN. INFO.:			US 1999-161232P	P	19991022
			US 2000-693783	A	20001019
			WO 2000-US29126	W	20001020

L10 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:247374 CAPLUS
DOCUMENT NUMBER: 134:276523
TITLE: Hypoxia-related human genes and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Denko, Nicholas C.; Giaccia, Amato J.; Green, Christopher J.; Laderoute, Keith R.; Schindler, Cornelia; Koong, Albert Ching-Wei
PATENT ASSIGNEE(S): Varian Associates, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023426	A2	20010405	WO 2000-US27189	20001002
WO 2001023426	A3	20011101		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-410375 A 19990930

L10 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:748205 CAPLUS
DOCUMENT NUMBER: 133:361435
TITLE: Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumors
AUTHOR(S): Kivela, Antti J.; Parkkila, Seppo; Saarnio, Juha; Karttunen, Tuomo J.; Kivela, Jyrki; Parkkila, Anna-Kaisa; Pastorekova, Silvia; Pastorek, Jaromir; Waheed, Abdul; Sly, William S.; Rajaniemi, Hannu
CORPORATE SOURCE: Department of Anatomy and Cell Biology, University of Oulu, Oulu, 90014, Finland
SOURCE: Histochemistry and Cell Biology (2000), 114(3), 197-204
CODEN: HCBIFP; ISSN: 0948-6143
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 07:53:57 ON 28 AUG 2007)

FILE 'CAPLUS' ENTERED AT 07:54:12 ON 28 AUG 2007
L1 1 S US 20040146955/PN
SEL RN

FILE 'REGISTRY' ENTERED AT 07:54:29 ON 28 AUG 2007
L2 108 S E1-E108

FILE 'CAPLUS' ENTERED AT 07:54:49 ON 28 AUG 2007
L3 23381 S L2
L4 10414 S L2/BIOL
L5 799250 S CANCER? OR TUMOR? OR NEOPLAS?
L6 909 S L4 AND L5
L7 553334 S DIAG?
L8 57089 S L7 (L) L5
L9 181 S L8 AND L4
L10 23 S L9 NOT PY>2002

=> s l10 and inhibit?

```
       1955429 INHIBIT?
L11          9 L10 AND INHIBIT?

=> d ibib ab 1-9

L11  ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2002:510395  CAPLUS
DOCUMENT NUMBER:         138:104572
TITLE:                   Molecular determinants of human uveal melanoma
                         invasion and metastasis
AUTHOR(S):               Seftor, Elisabeth A.; Meltzer, Paul S.; Kirschmann,
                         Dawn A.; Pe'er, Jacob; Maniotis, Andrew J.; Trent,
                         Jeffrey M.; Folberg, Robert; Hendrix, Mary J. C.
CORPORATE SOURCE:        Department of Anatomy and Cell Biology, College of
                         Medicine and The Holden Comprehensive Cancer Center,
                         University of Iowa, Iowa City, IA, USA
SOURCE:                  Clinical & Experimental Metastasis (2002), 19(3),
                         233-246
                         CODEN: CEXMD2; ISSN: 0262-0898
PUBLISHER:               Kluwer Academic Publishers
DOCUMENT TYPE:           Journal
LANGUAGE:                English
AB   The mol. anal. of cancer has benefited tremendously from the
     sequencing of the human genome integrated with the science of
     bioinformatics.  Microarray anal. technol. has the potential to classify
     tumors based on the differential expression of genes.  In the
     current study, a collaborative, multidisciplinary approach was utilized to
     study the mol. determinants of human uveal melanoma invasion and
     metastasis.  Uveal melanoma is considered the most common primary
     intraocular cancer in adults, resulting in the death of approx.
     50% of patients affected.  Unfortunately, at the time of diagnosis
     , many patients already harbor microscopic metastases, thus underscoring a
     critical need to identify prognostic markers indicative of metastatic
     potential.  The investigative strategy consisted of isolating highly
     invasive vs. poorly invasive uveal melanoma cells from a heterogeneous
     tumor derived from cells that had metastasized from the eye to the
     liver.  The heterogeneous tissue explant MUM-2 led to the derivation of
     two clonal cell lines: MUM-2B and MUM-2C.  Further morphol. and functional
     analyses revealed that the MUM-2B cells were epithelioid, interconverted
     (expressing mesenchymal and epithelial phenotypes) highly invasive, and
     demonstrated vasculogenic mimicry.  The MUM-2C cells were spindle-like,
     expressed only a vimentin mesenchymal phenotype, poorly invasive, and were
     incapable of vasculogenic mimicry.  The mol. anal. of the MUM-2B vs. the
     MUM-2C clones resulted in the differential expression of 210 known genes.
     Overall, the mol. signature of the MUM-2B cells resembled that of multiple
     phenotypes - similar to a pluripotent, embryonic-like genotype.
     Validation of select genes that were upregulated and down-regulated was
     conducted by semiquant. RT-PCR measurement.  This study provides a mol.
     profile that will hopefully lead to the development of new mol. targets
     for therapeutic intervention and possible diagnostic markers to
     predict the clin. outcome of patients with uveal melanoma.
REFERENCE COUNT:         70    THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11  ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:        2001:743200  CAPLUS
DOCUMENT NUMBER:         136:35588
TITLE:                   Secreted and cell surface genes expressed in benign
                         and malignant colorectal tumors
AUTHOR(S):               Buckhaults, Phillip; Rago, Carlo; St. Croix, Brad;
                         Romans, Katharine E.; Saha, Saurabh; Zhang, Lin;
                         Vogelstein, Bert; Kinzler, Kenneth W.
```

CORPORATE SOURCE: Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA
SOURCE: Cancer Research (2001), 61(19), 6996-7001
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Serial anal. of gene expression was used to identify transcripts encoding secreted or cell surface proteins that were expressed in benign and malignant tumors of the colorectum. A total of 290,394 tags were analyzed from normal, adenomatous, and cancerous colonic epithelium. Of the 21,343 different transcripts observed, 957 were found to be differentially expressed between normal tissue and adenoma or between normal tissue and cancer. Forty-nine transcripts were elevated ≥20-fold in adenomas, 40 transcripts were elevated ≥20-fold in cancers, and 9 transcripts were elevated ≥20-fold in both. Products of six of these nine transcripts (TGFBI, LYS, RDP, MIC-1, REGA, and DEHL) were predicted to be secreted or to reside on the cell surface, and these were analyzed in more detail. The abnormal expression levels predicted by serial anal. of gene expression were confirmed by quant. PCR analyses of each of these six genes. Moreover, the cell types responsible for the elevated expression were identified by in situ hybridization and by PCR analyses of epithelial cells immunoaffinity purified from primary tumors. This study extends knowledge of the differences in gene expression that underlie various stages of neoplasia and suggests specific diagnostic approaches that may be useful for the early detection of colorectal neoplasia .
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:361504 CAPLUS
DOCUMENT NUMBER: 135:146678
TITLE: Carbonic anhydrase inhibitors
AUTHOR(S): Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE: Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE: Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2001), 1(1), 61-97
CODEN: CMCIC8; ISSN: 1568-0134
PUBLISHER: Bentham Science Publishers Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 151 refs. CAs (EC 4.2.1.1) are wide-spread zinc enzymes, present in mammals in at least 14 different isoforms. Some of these isoenzymes are cytosolic (CA I, CA II, CA III, CA VII), others are membrane-bound (CA IV, CA IX, CA XII and CA XIV), CA V is mitochondrial and CA VI is secreted in the saliva. Three acatalytic forms are also known (CARP VIII, CARP X and CARP XI). Several important physiol. and physio-pathol. functions are played by many CA isoenzymes, which are strongly inhibited by aromatic and heterocyclic sulfonamides. The catalytic and inhibition mechanisms of these enzymes are understood in great detail, and this greatly helped the design of potent inhibitors, some of which possess important clin. applications. The use of such enzyme inhibitors as antiglaucoma drugs will be discussed in detail, together with the recent developments that led to isoenzyme-specific and organ-selective inhibitors. A recent discovery is connected with the involvement of CAs and their sulfonamide inhibitors in cancer: several potent sulfonamide inhibitors inhibited the growth of a multitude of tumor cells in vitro and in vivo, constituting thus interesting

leads for developing novel antitumor therapies. Furthermore, some other classes of compds. that interact with CAs have recently been discovered, some of which possess modified sulfonamide or hydroxamate moieties. Some sulfonamides have also applications as diagnostic tools, in PET and MRI. Future prospects for drug design applications for inhibitors of these ubiquitous enzymes will also be discussed.

REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:320060 CAPLUS
DOCUMENT NUMBER: 134:339179
TITLE: Nucleic acids and proteins associated with cancer as antitumor targets
INVENTOR(S): Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David
PATENT ASSIGNEE(S): Lifespan Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030964	A2	20010503	WO 2000-US29126	20001020
WO 2001030964	A3	20010809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001013397	A	20010508	AU 2001-13397	20001020
PRIORITY APPLN. INFO.:			US 1999-161232P P	19991022
			US 2000-693783 A	20001019
			WO 2000-US29126 W	20001020

AB This invention relates to the discovery of nucleic acids associated with cell proliferation, neoplasia, cell transformation, malignant tumor formation and metastasis and uses therefor. The present invention provides a method for cancer diagnosing by detecting the overexpression or the underexpression of a cancer -associated mRNA in the tissue of interest, preferably in liver, breast, prostate, kidney and colon. In another aspect, the invention provides methods for arresting cancer and a method for identifying a modulators of cancer development.

L11 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:247374 CAPLUS
DOCUMENT NUMBER: 134:276523
TITLE: Hypoxia-related human genes and their encoded proteins and diagnostic and therapeutic uses
INVENTOR(S): Denko, Nicholas C.; Giaccia, Amato J.; Green, Christopher J.; Laderoute, Keith R.; Schindler, Cornelia; Koong, Albert Ching-Wei
PATENT ASSIGNEE(S): Varian Associates, Inc., USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023426	A2	20010405	WO 2000-US27189	20001002
WO 2001023426	A3	20011101		

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-410375 A 19990930

AB The polynucleotide and polypeptide sequences of two novel hypoxia-inducible human and murine genes, HIG1 and HIG2, are described. In addition, a number of known genes and ESTs are established as being hypoxia-inducible and hypoxia-repressible. Polynucleotide and polypeptide arrays comprising the hypoxia-inducible and hypoxia-repressible gene sequences, proteins, or antibodies which specifically bind the proteins are disclosed. Methods for using the hypoxia-inducible and hypoxia-repressible gene sequences and proteins, and arrays thereof, to diagnose and treat hypoxia-related conditions such as cancer and ischemia are also provided.

L11 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1996:262841 CAPLUS
DOCUMENT NUMBER: 124:314359
TITLE: A marker antigen for non-small cell lung cancer and a cDNA encoding it and their uses
INVENTOR(S): Torczynski, Richard M.; Bollon, Arthur P.
PATENT ASSIGNEE(S): Cytoclonal Pharmaceutics, Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9602552	A1	19960201	WO 1995-US9145	19950719
W: AU, BR, CA, CN, FI, JP, KE, KR, LK, MN, MX, NO, NZ, PL, RU, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5589579	A	19961231	US 1994-276919	19940719
CA 2195403	A1	19960201	CA 1995-2195403	19950719
AU 9533592	A	19960216	AU 1995-33592	19950719
AU 700915	B2	19990114		
EP 804451	A1	19971105	EP 1995-930093	19950719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
BR 9508417	A	19971118	BR 1995-8417	19950719
JP 10503087	T	19980324	JP 1995-505257	19950719
US 5773579	A	19980630	US 1997-776088	19970121

PRIORITY APPLN. INFO.: US 1994-276919 A 19940719
WO 1995-US9145 W 19950719

AB A cDNA and the corresponding protein for a novel protein specific for

human lung cancer cells are described. This gene is expressed at a much higher level in these cells than in normal lung cells, other normal tissues and other tumor cell lines tested. Genes for forms of the protein lacking a membrane spanning region and with amino acid substitutions affecting a potential phosphorylation site are also described. Nucleic acid probes for the detection of lung cancer cells from tissue biopsy and body fluids such as serum sputum and bronchial washings are derived from the gene. Manufacture of the antigen in a host cell and its use as an immunogen in antibody production for test applications is described. An ELISA test to measure shed antigen present in patient samples as well as an enzyme test to measure activity in specimens are also described. The protein has features common to human carbonic anhydrases and is named HCAVIII (human carbonic anhydrase VIII).

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:881452 CAPLUS
DOCUMENT NUMBER: 123:296614
TITLE: Pretargeting methods and compounds with reduced immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols
INVENTOR(S): Graves, Scott S.; Bjorn, Michael J.; Reno, John M.; Axworthy, Donald B.; Fritzberg, Alan R.; Theodore, Louis J.
PATENT ASSIGNEE(S): Neorx Corp., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9515770	A1	19950615	WO 1994-US14223	19941209

W: CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1993-164302 A 19931209
AB Methods, compds., compns., and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods and agents are provided for reducing the immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols. Preparation of various conjugates for use in the invention is included. Examples include e.g. in vivo anal. of a radiolabeled chelate-biotin conjugate administered after antibody pretargeting, clearing agent evaluation, two- and three-step pretargeting methodol., administration of a monoclonal antibody (MAb)-streptavidin conjugate in humans, and immunosuppression of MAb-containing conjugates.

L11 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:429021 CAPLUS
DOCUMENT NUMBER: 122:179383
TITLE: Identification of ligands by selective amplification of cells transfected with receptors
INVENTOR(S): Brann, Mark Robert
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502823	A1	19950126	WO 1994-US7900	19940713
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SE, SK, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IL 110298	A	19990411	IL 1994-110298	19940712
CA 2167048	A1	19950126	CA 1994-2167048	19940713
CA 2167048	C	20010925		
AU 9473330	A	19950213	AU 1994-73330	19940713
AU 679253	B2	19970626		
EP 708922	A1	19960501	EP 1994-923478	19940713
EP 708922	B1	19990310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09500023	T	19970107	JP 1995-504713	19940713
JP 3102571	B2	20001023		
AT 177535	T	19990315	AT 1994-923478	19940713
ES 2129658	T3	19990616	ES 1994-923478	19940713

PRIORITY APPLN. INFO.: US 1993-91694 A 19930713
WO 1994-US7900 W 19940713

AB A method of detecting a substance capable of acting as a ligand comprises (a) incubating, under conditions permitting cell amplification, cells transfected with DNA coding for a receptor capable of influencing cell amplification in response to a ligand, the cells containing a marker of cell amplification, with a test substance which is a potential agonist or antagonist of the receptor, and (b) after a period of time sufficient to permit cell amplification, determining the presence or absence of amplification of cells containing the marker relative to cells not containing the marker. Thus, 3T3 cells were transfected with DNA for the trk A receptor, stimulation of which activates tyrosine phosphorylation, and with DNA for β-galactosidase. Incubation of the cells with NGF, an agonist for the trk receptor, dose-dependently induced growth of the cells over the range 10-12-10-9M, as indicated by β-galactosidase activity.

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:100166 CAPLUS
DOCUMENT NUMBER: 116:100166
TITLE: Method for increasing blood-brain barrier permeability by intravenous coadministration of bradykinin agonist
INVENTOR(S): Malfroy-Camine, Bernard; Smart, Janet L.
PATENT ASSIGNEE(S): Alkermes, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9116355	A1	19911031	WO 1991-US2772	19910423
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5112596	A	19920512	US 1990-512913	19900423
AU 9178606	A	19911111	AU 1991-78606	19910423
AU 650020	B2	19940609		
EP 528891	A1	19930303	EP 1991-909190	19910423
EP 528891	B1	20000705		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

JP 05506859	T	19931007	JP 1991-509000	19910423
AT 194289	T	20000715	AT 1991-909190	19910423
ES 2147722	T3	20001001	ES 1991-909190	19910423
US 5506206	A	19960409	US 1993-121058	19930913
GR 3034351	T3	20001229	GR 2000-402039	20000906
PRIORITY APPLN. INFO.:			US 1990-512913 A2	19900423
			US 1991-690522 A3	19910423
			WO 1991-US2772 A	19910423

AB The permeability of the blood-brain barrier of a host to a (therapeutic or diagnostic) mol. is increased by i.v. coadministration of a bradykinin agonist of blood-brain permeability. [Hyp3, Thi5 4-Me-Tyr8Ψ(CH2NH)Arg9] bradykinin (A-7; Thi = thienylalanine; preparation given) increased the brain uptake of loperamide, domperidone, 3H-AZT, 99mTc-DISIDA, and others. Rats with brain tumor implants survived longer when treated with cisplatin coadministered with A-7.

=> d ibib ab kwic 3, 7, 9

L11 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2001:361504 CAPLUS
DOCUMENT NUMBER:	135:146678
TITLE:	Carbonic anhydrase inhibitors
AUTHOR(S):	Supuran, Claudiu T.; Scozzafava, Andrea
CORPORATE SOURCE:	Universita degli Studi, Laboratorio di Chimica Inorganica e Bioinorganica, Florence, I-50121, Italy
SOURCE:	Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents (2001), 1(1), 61-97 CODEN: CMCIC8; ISSN: 1568-0134
PUBLISHER:	Bentham Science Publishers Ltd.
DOCUMENT TYPE:	Journal; General Review
LANGUAGE:	English

AB A review with 151 refs. CAs (EC 4.2.1.1) are wide-spread zinc enzymes, present in mammals in at least 14 different isoforms. Some of these isoenzymes are cytosolic (CA I, CA II, CA III, CA VII), others are membrane-bound (CA IV, CA IX, CA XII and CA XIV), CA V is mitochondrial and CA VI is secreted in the saliva. Three acatalytic forms are also known (CARP VIII, CARP X and CARP XI). Several important physiol. and physio-pathol. functions are played by many CA isoenzymes, which are strongly inhibited by aromatic and heterocyclic sulfonamides. The catalytic and inhibition mechanisms of these enzymes are understood in great detail, and this greatly helped the design of potent inhibitors, some of which possess important clin. applications. The use of such enzyme inhibitors as antiglaucoma drugs will be discussed in detail, together with the recent developments that led to isoenzyme-specific and organ-selective inhibitors. A recent discovery is connected with the involvement of CAs and their sulfonamide inhibitors in cancer: several potent sulfonamide inhibitors inhibited the growth of a multitude of tumor cells in vitro and in vivo, constituting thus interesting leads for developing novel antitumor therapies. Furthermore, some other classes of compds. that interact with CAs have recently been discovered, some of which possess modified sulfonamide or hydroxamate moieties. Some sulfonamides have also applications as diagnostic tools, in PET and MRI. Future prospects for drug design applications for inhibitors of these ubiquitous enzymes will also be discussed.

REFERENCE COUNT: 152 THERE ARE 152 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

TI Carbonic anhydrase inhibitors

AB A review with 151 refs. CAs (EC 4.2.1.1) are wide-spread zinc enzymes,

present in mammals in at least 14 different isoforms. Some of these isoenzymes are cytosolic (CA I, CA II, CA III, CA VII), others are membrane-bound (CA IV, CA IX, CA XII and CA XIV), CA V is mitochondrial and CA VI is secreted in the saliva. Three acatalytic forms are also known (CARP VIII, CARP X and CARP XI). Several important physiol. and physio-pathol. functions are played by many CA isoenzymes, which are strongly inhibited by aromatic and heterocyclic sulfonamides. The catalytic and inhibition mechanisms of these enzymes are understood in great detail, and this greatly helped the design of potent inhibitors, some of which possess important clin. applications. The use of such enzyme inhibitors as antiglaucoma drugs will be discussed in detail, together with the recent developments that led to isoenzyme-specific and organ-selective inhibitors. A recent discovery is connected with the involvement of CAs and their sulfonamide inhibitors in cancer: several potent sulfonamide inhibitors inhibited the growth of a multitude of tumor cells in vitro and in vivo, constituting thus interesting leads for developing novel antitumor therapies. Furthermore, some other classes of compds. that interact with CAs have recently been discovered, some of which possess modified sulfonamide or hydroxamate moieties. Some sulfonamides have also applications as diagnostic tools, in PET and MRI. Future prospects for drug design applications for inhibitors of these ubiquitous enzymes will also be discussed.

ST review carbonic anhydrase inhibitor antiglaucoma antitumor therapy

IT Antiglaucoma agents
Antitumor agents
Drug design
(carbonic anhydrase inhibitors)

IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(carbonic anhydrase inhibitors)

L11 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1995:881452 CAPLUS
DOCUMENT NUMBER: 123:296614
TITLE: Pretargeting methods and compounds with reduced immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols
INVENTOR(S): Graves, Scott S.; Bjorn, Michael J.; Reno, John M.; Axworthy, Donald B.; Fritzberg, Alan R.; Theodore, Louis J.
PATENT ASSIGNEE(S): Neorx Corp., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9515770	A1	19950615	WO 1994-US14223	19941209
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1993-164302	A 19931209

AB Methods, compds., compns., and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods and agents are provided for reducing the immunogenicity of targeting moiety-anti-ligand conjugates or other components employed in diagnostic and therapeutic pretargeting protocols. Preparation of various conjugates for

use in the invention is included. Examples include e.g. in vivo anal. of a radiolabeled chelate-biotin conjugate administered after antibody pretargeting, clearing agent evaluation, two- and three-step pretargeting methodol., administration of a monoclonal antibody (MAb)-streptavidin conjugate in humans, and immunosuppression of MAb-containing conjugates.

IT Neoplasm inhibitors
(conjugates with biotin; therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

IT Intestine, neoplasm
(colon, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

IT Neoplasm inhibitors
(lung small-cell carcinoma, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

IT Lung, neoplasm
(small-cell carcinoma, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

IT Lung, neoplasm
(small-cell carcinoma, inhibitors, therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

IT 50-18-0, Cyclophosphamide 52-53-9, Verapamil 58-85-5D, Biotin, conjugates with therapeutic and linker 59-05-2, Methotrexate 59-23-4D, Galactose, conjugates with albumin and biotin 59-66-5, Acetazolamide 114-07-8, Erythromycin 364-62-5, Metoclopramide 446-86-6, Azathioprine 4759-48-2, Isotretinoin 9013-20-1D, Streptavidin, targeting moiety conjugates 10043-49-9D, Gold-198, biotin conjugates, biological studies 10043-66-0D, Iodine-131, biotin conjugates, biological studies 10098-91-6D, Yttrium-90, biotin conjugates, biological studies 14265-75-9D, Lutetium-177, biotin conjugates, biological studies 14378-26-8D, Rhenium-188, biotin conjugates, biological studies 14913-49-6D, Bismuth-212, biotin conjugates, biological studies 14913-89-4D, biotin conjugates, biological studies 14998-63-1D, Rhenium-186, biotin conjugates, biological studies 15092-94-1D, Lead-212, biotin conjugates, biological studies 15715-08-9D, Iodine-123, biotin conjugates, biological studies 15750-15-9D, Indium-111, biotin conjugates, biological studies 15755-39-2D, Astatine-211, biotin conjugates, biological studies 15757-86-5D, Copper-67, biotin conjugates, biological studies 15766-00-4D, Samarium-153, biotin conjugates, biological studies 24280-93-1, Mycophenolic acid 25322-68-3D, streptavidin derivs. 42399-41-7, Diltiazem 51632-96-3D, Europium-169, biotin conjugates, biological studies 53123-88-9, Rapamycin 55985-32-5, Nicardipine 59865-13-3, Cyclosporin A 65277-42-1, Ketoconazole 86386-73-4, Fluconazole 89149-10-0, Deoxyspergualin 104987-11-3, FK506
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic and diagnostic pretargeting methods and compds., and conjugate preparation and evaluation)

L11 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:100166 CAPLUS
DOCUMENT NUMBER: 116:100166
TITLE: Method for increasing blood-brain barrier permeability by intravenous coadministration of bradykinin agonist
INVENTOR(S): Malfroy-Camine, Bernard; Smart, Janet L.
PATENT ASSIGNEE(S): Alkermes, Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9116355	A1	19911031	WO 1991-US2772	19910423
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5112596	A	19920512	US 1990-512913	19900423
AU 9178606	A	19911111	AU 1991-78606	19910423
AU 650020	B2	19940609		
EP 528891	A1	19930303	EP 1991-909190	19910423
EP 528891	B1	20000705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05506859	T	19931007	JP 1991-509000	19910423
AT 194289	T	20000715	AT 1991-909190	19910423
ES 2147722	T3	20001001	ES 1991-909190	19910423
US 5506206	A	19960409	US 1993-121058	19930913
GR 3034351	T3	20001229	GR 2000-402039	20000906
PRIORITY APPLN. INFO.:			US 1990-512913 A2	19900423
			US 1991-690522 A3	19910423
			WO 1991-US2772 A	19910423

AB The permeability of the blood-brain barrier of a host to a (therapeutic or diagnostic) mol. is increased by i.v. coadministration of a bradykinin agonist of blood-brain permeability. [Hyp3, Thi5 4-Me-Tyr8Ψ(CH2NH)Arg9] bradykinin (A-7; Thi = thienylalanine; preparation given) increased the brain uptake of loperamide, domperidone, 3H-AZT, 99mTc-DISIDA, and others. Rats with brain tumor implants survived longer when treated with cisplatin coadministered with A-7.

AB The permeability of the blood-brain barrier of a host to a (therapeutic or diagnostic) mol. is increased by i.v. coadministration of a bradykinin agonist of blood-brain permeability. [Hyp3, Thi5 4-Me-Tyr8Ψ(CH2NH)Arg9] bradykinin (A-7; Thi = thienylalanine; preparation given) increased the brain uptake of loperamide, domperidone, 3H-AZT, 99mTc-DISIDA, and others. Rats with brain tumor implants survived longer when treated with cisplatin coadministered with A-7.

IT Neoplasm inhibitors
(cisplatin as, bradykinin agonist increasing blood-brain barrier permeability in relation to)

IT Brain, neoplasm
(inhibitors, cisplatin as, bradykinin agonist increasing blood-brain barrier permeability in relation to)

IT 57-50-1, Sucrose, biological studies 9001-03-0 9001-99-4 9040-95-3, 3H-Inulin 902457-23-2
RL: BIOL (Biological study)
(blood-brain barrier permeability to, bradykinin agonist effect on, mol. weight in relation to)

IT 62571-86-2, Captopril
RL: BIOL (Biological study)
(bradykinin degradation inhibition with, blood-brain barrier permeability to cisplatin in relation to)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.78	73.00

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-9.36

STN INTERNATIONAL LOGOFF AT 08:06:11 ON 28 AUG 2007